Epidermal growth factor receptor and anaplastic lymphoma kinase mutations detected by immunohistochemistry in lung adenocarcinoma in patients from Johannesburg by Vorajee, Dr Naseema
Epidermal growth factor receptor and anaplastic lymphoma kinase 
mutations detected by immunohistochemistry in lung 
adenocarcinoma in patients from Johannesburg  
 
Dr Naseema Vorajee 
Wits student number: 92102330w 
Year of study: 2014/2017 
Date of final submission: 19 July 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, 
University of the Witwatersrand, in partial fulfilment of the 
requirement for the degree of Master of Medicine in Anatomical 
Pathology 
 
 
ii 
 
CANDIDATE’S DECLARATION 
 
I, Naseema Ismail Vorajee (Student number: 9102330w) am a student 
registered for the degree of MMed (Anatomical Pathology) in the 
academic years 2014/2017.  
I hereby declare the following:  
I am aware that plagiarism (the use of someone else’s work without 
their permission and/or without acknowledging the original source) is 
wrong.  
I confirm that the work submitted for assessment for the above 
degree is my own unaided work except where I have explicitly 
indicated otherwise.  
I have followed the required conventions in referencing the thoughts 
and ideas of others. I understand that the University of the 
Witwatersrand may take disciplinary action against me if there is a 
belief that this is not my own unaided work or that I have failed to 
acknowledge the source of the ideas or words in my writing. 
 
     
Signature        Date: 19/07/2017 
iii 
 
DEDICATION 
 
 I dedicate this research report to  
  my beloved husband Junaid, 
   my darling sons Aadil and Isa, 
    and my dear parents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT 
Lung cancer is the leading cause of cancer related death worldwide. Despite the 
availability of conventional cytotoxic chemotherapy, prognosis even with treatment is 
poor. Treatment targeted to specific molecular alterations called Tyrosine kinase 
inhibitors (TKI) has been found to be effective in certain subtypes of non small cell 
carcinoma (NSCC) that have the epidermal growth factor receptor (EGFR) gene 
mutation and the anaplastic lymphoma kinase (ALK) translocation. EGFR mutations are 
seen in 18-25% of lung adenocarcinomas (AC)s and are represented in more than 90% 
of cases by the E746_A750 deletion on exon 19 and the L858R point mutation on exon 
21. The ALK translocation is seen in 2-7% of lung cancers, and involves the EML4-ALK 
fusion gene product. Immunohistochemistry (IHC) has the potential of being used as an 
initial screening tool that can facilitate a shorter diagnostic time and fast track treatment 
options. Little is known about the mutational status of patients with these mutations in 
South Africa. This study examines the use of IHC as a means of detecting the most 
common EGFR mutations and the ALK translocation in lung cancer.  
Method: Biopsies of patients from the Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) and Helen Joseph Hospital (HJH) sent to the National Institute for 
Occupational Health (NIOH) from 1st January 2008 to 30th June 2014 were reviewed. A 
total of 3901 histology reports were accessed. There were 297 lung carcinomas 
comprising 117 (39%) ACs and 128 (46%) squamous carcinomas (SCC)s. A total of 
119 biopsies comprising 107 ACs (90%), 4 (3%) adenosquamous carcinomas 
(ADSCC)s, 1 (1%) large cell carcinoma (LC) and 7 (6%) NSCC (nos.) comprised the 
cohort. One hundred and eleven biopsies were available for mutational analysis, as 8 
biopsies were excluded due to insufficient tissue availability. The mutation specific 
antibodies, EGFR SP111 and EGFR SP125 were used to detect the E746_A750 
deletion and the L858R point mutations respectively. The high affinity ALK D5F3 
antibody was used for the detection of the EML4-ALK translocation.  
Results: The majority of patients in the study were Black males (61%). There were no 
Asians. The mean age was 58 years with a SD of 11.5. Most patients (76%) were 
younger than 65 years. The EGFR IHC stain was positive in 10/111 (9%) biopsies, of 
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which 8 were from Blacks, 6 were from males, 4 were from smokers and 2 were from 
non-smokers. There was however no significant difference between the proportions of 
Black or White and male or female among those who tested positive to EGFR and those 
who tested negative (p>0.05) and no significant association was found between the 
variables age, sex and smoking history (p>0.05). The ALK IHC was positive in 8 (7%) 
patients. All 8 patients were Black, six were male, four had a smoking history and two 
patients were non-smokers. A significant association was found between race and 
positive ALK IHC (p=0.03). There was no significant association with age (p=0.081). 
The acinar growth pattern was found in 80% of the EGFR IHC positive biopsies, with 
10% of biopsies showing either lepidic, solid or micropapillary patterns. Although 
several growth patterns were seen in ALK IHC positive biopsies, there was a slight 
predominance of the acinar and solid growth patterns.  
Discussion: The EGFR IHC was positive in 9% of patients, which is half the number of 
cases described in literature from Western and Eastern countries, where the prevalence 
is usually more than 18%. There may be several reasons for the lower rate of EGFR 
IHC positivity. Antigen degradation, intratumoral heterogeneity and a low sensitivity of 
the EGFR IHC antibody may have contributed. The demographic profile of patients with 
positive result following EGFR IHC differs from the literature although the results were 
not found to be statistically significant. The sensitivity of the EGFR IHC test as 
described in the literature ranges from as low as 61% to 100%. A good correlation 
between EGFR IHC and EGFR polymerase chain reaction, in confirming the presence 
of the EGFR mutation, is described with biopsies that show strong positive cytoplasmic 
staining with IHC. Strong positive cytoplasmic staining with EGFR IHC was found in 
these 10 biopsies. The ALK IHC result was positive in 7% of patients, which is on the 
upper limit of the 2-7% rate recorded in most literature. A significant association was 
found with Blacks. Although an association with younger patients and the ALK mutation 
was found, this was not statistically significant. As ALK IHC is associated with an almost 
100% sensitivity and specificity, there is a possibility that the ALK mutational rate in 
South African Black patients may be higher than the rate in other international 
populations. SCC is the more common subtype of lung cancer (46%) compared to AC 
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(39%) in this group of patients from Johannesburg. This differs from studies in Cape 
Town and international studies, where a shift in trend from SCC to AC is observed.     
Conclusion: This study confirms the presence of the EGFR mutation and ALK 
translocation in patients with adenocarcinoma from Johannesburg using 
immunohistochemistry. We have proposed a diagnostic algorithm for patients with lung 
cancer in South Africa where EGFR IHC and ALK IHC can be used as rapid initial 
screening tests to identify patients with the EGFR mutation and ALK translocation 
respectively, provided established guidelines for IHC interpretation are followed. This 
approach allows patients with lung cancer who have the EGFR and ALK mutations to 
be fast tracked towards receiving targeted therapy. 
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Chapter 1: INTRODUCTION 
 
1.1 Background 
Lung cancer is the most common visceral cancer in males worldwide and 
has been for several decades, with an estimated 1.8 million new cases 
recorded for 2012 by the International Agency for Research on Cancer, 
58% of which occurred in the less developed regions (Ferlay et al., 2012). 
Lung cancer was found to be responsible for approximately one in five 
deaths related to cancer, with an estimated mortality of 1.59 million.  
 
The mortality of lung cancer recorded for South Africa in 2012 was 13.7%;  
the most common cause of cancer related death in males (surpassing 
prostate cancer) and the third most common cause of cancer related death 
in females (following cervical and breast cancer) (Ferlay et al., 2012). 
 
The overall prognosis of patients diagnosed with lung cancer is poor. The 
five year survival for lung cancer of all stages in the United States in 2004 
was 16.8% (Ridge, McErlean and Ginsberg, 2013). The poor prognosis is 
as a result of late presentation when surgery is precluded and poor results 
obtained from standard platinum-based chemotherapy regimens. There is 
therefore a need to identify lung cancer at an earlier stage and improve 
current treatment regimens. Lung cancer screening programmes for early 
detection of lung cancer are not well established and may not be a feasible 
option in a resource poor country such as South Africa. The search for a 
more effective treatment regimen prompted the undertaking of several 
clinical trials, which in the beginning of the 21st century saw the success of 
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targeted therapy using a certain group of drugs referred to as “Tyrosine 
kinase inhibitor (TKI) therapy” in some patients diagnosed with lung cancer 
(Cheng et al., 2012). Patients who showed a favourable response were 
found to have non small cell carcinoma (NSCC) of the lung. NSCC and 
small cell lung carcinoma (SCLC) are histologic subtypes of lung cancer. 
NSCC is more common than small cell lung cancer (SCLC) and is further 
sub-classified into squamous carcinoma (SCC), adenocarcinoma (AC), 
adenosquamous carcinoma (ADSCC) and large cell carcinoma (LC). 
Patients with NSCC who showed a positive response to TKIs were found to 
have either AC, ADSCC or LC subtypes, and on further investigation, were 
found to have a mutation in the epidermal growth factor receptor (EGFR) 
gene. Studies also revealed that most patients with lung cancer who had 
the EGFR mutation had a similar demographic profile: they were female, 
non-smokers and predominantly of Asian descent (Cheng et al., 2012).   
 
Similarly, in 2007 treatment success with another TKI, crizotinib, was found 
in some patients with NSCC. On further investigation, these patients were 
found to harbour a particular mutation involving the anaplastic lymphoma 
kinase (ALK) gene (Soda et al., 2007). The EGFR mutation was absent. 
Patients with lung cancer who responded to crizotinib were also found to 
have a similar demographic profile with respect to younger age (less than 
65 years) and non-smoking history however there was no association with 
Asian ethnicity (Kwak et al., 2010).      
 
Targeted therapy has thus changed the approach to patients with lung 
cancer. Current international recommendations by Lindeman et al. (2013) 
include testing for the presence of the EGFR mutation and ALK 
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translocation in lung resection specimens for all lung ACs including any 
mixed lung cancer that may have an AC component such as 
adenosquamous carcinoma (ADSCC) and combined small cell carcinoma 
with an AC component (a combined small cell carcinoma has both SCLC 
and NSCC components. The NSCC component may be an AC, SCC or LC 
(Travis et al., 2015)). Testing is also recommended on tumours that do not 
show any clear morphological or immunohistochemical differentiation. 
These tumours are referred to as NSCC (not otherwise specified, nos.) if 
found on a small biopsy specimen and large cell carcinoma (LC) if found in 
a resection specimen. This approach allows patients with lung cancer, who 
may have an AC component that is difficult to diagnose morphologically or 
with immunohistochemistry, a chance of benefitting from targeted therapy. 
These molecular tests are not recommended for lung cancers in resection 
specimens that do not have an adenocarcinoma component, such as pure 
squamous cell carcinoma (SCC) and small cell carcinoma (SCLC), as most 
of these tumours were found not to harbour the EGFR mutation or ALK 
translocation (Lindeman et al., 2013).  
 
The EGFR mutation and ALK translocation are found in a subset of 
patients with lung cancer who usually do not have a smoking history. 
Smoking however remains a significant contributor to the incidence of lung 
cancer. A shift in trend in lung cancers from being predominantly of the 
squamous subtype to the adenocarcinoma subtype has been observed in 
several developed countries as a result of a change in smoking practices. 
Other possible causes of lung cancer include occupational exposure to 
chemicals, dust and fibres.  A recent study by Kradin, Lafrate and Christiani 
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(2017) describes the presence of the EGFR mutation in three patients who 
had no smoking history but were exposed to asbestos fibres.   
 
1.2 Problem statement 
1). Patients in South Africa who have lung cancer present at an advanced 
stage (Nanguzgambo et al., 2011) 
2). Response of lung cancer to standard chemotherapy is poor   
3). Targeted therapy is promising for patients who have the specific 
mutations 
4). Little is known about the EGFR mutation and ALK translocation rate in 
NSCC in South Africa and if these mutations are present, do they occur in 
lung cancers from patients who have a similar demographic profile as 
described in literature from other countries. Knowledge on the prevalence 
of the EGFR mutation in the South African population is limited to a single 
study (Chan, 2015) whilst there is no data on the ALK translocation.   
5). It is uncertain whether the shift in trend in lung cancer from SCC to AC 
observed in other countries is true for South Africa.  
6). Little is known about the relationship between the presence of the 
EGFR mutation and ALK translocation and occupational history.  
 
1.3 Rationale 
1). By identifying the EGFR mutation and ALK translocation in patients with 
lung cancer, we can identify patients who may benefit from targeted 
therapy.  
2). Testing for these mutations is not routinely performed by the National 
Health Laboratory Service (NHLS) and there is no current protocol or 
recommendations for the testing of these mutations in South Africa. Current 
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international recommendations for the detection of the EGFR mutation 
include polymerase chain reaction (PCR) and fluorescence in situ 
hybridisation (FISH) for the detection of the ALK translocation (Lindeman et 
al., 2013). Immunohistochemistry (IHC) is rapid, convenient, accessible 
and affordable and may be used as an initial tool to identify these 
mutations.    
 
1.4 Aim 
The aim is to evaluate the use immunohistochemistry to detect specific 
mutations in lung cancer in South African patients for which targeted 
therapy may be a treatment option.   
       
1.5 Objectives 
1. To determine the prevalence of the EGFR mutation in lung AC, ADSCC, 
LC, NSCC (nos.) and combined tumours with an AC component using 
EGFR IHC.  
2. To determine the prevalence of the ALK translocation in lung AC, 
ADSCC, LC, NSCC (nos.) and combined tumours with an AC component 
using ALK IHC.  
3. To test the association between patient demographic characteristics 
(race, sex, age, smoking history and occupational history) and the 
presence of the EGFR mutation.  
4. To test the association between patient demographic characteristics 
(race, sex, age, smoking history and occupational history) and the 
presence of the ALK translocation.   
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5. To test the association between the morphological patterns of the 
different subtypes of NSCC (AC, ADSCC, LC, NSCC (nos.) and combined 
tumours with an AC component) and the presence of the EGFR mutation. 
6. To test the association between the morphological patterns of the 
different types of lung cancer (AC, ADSCC, LC, NSCC (nos.) and 
combined tumours with an AC component) and the presence of the ALK 
translocation. 
7. To determine the prevalence of SCC and AC.  
 
1.6 Significance 
There is only one published report by Chan (2015) on the EGFR mutational 
status of lung cancer in the South African population.  
 
Currently, targeted therapy for lung cancer is only available for selected 
patients who are either in the private sector or enrolled in clinical trials. If 
continued success with targeted therapy is shown, we expect targeted 
therapy drugs to become part of the standard treatment programme for all 
patients with lung cancer.  
 
The National Institute for Occupational Health (NIOH) is a division of the 
NHLS, which serves the public sector hospitals that treat more than 80% of 
the population of South Africa. The development of an affordable, 
accessible and effective method of detection of the EGFR mutation and 
ALK translocation is needed. This is particularly relevant to South Africa, 
where resources are limited and patient follow up is poor. 
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Chapter 2: LITERATURE REVIEW 
 
1). Lung cancer classification 
Historically, lung cancer has been classified by the World Health 
Organisation (WHO) into two main types: small cell lung carcinoma (SCLC) 
and non small cell lung carcinoma (NSCLC), which was based on 
differences in behaviour and treatment (Travis et al., 2004). Although 
NSCLC was further sub-classified into squamous carcinoma (SCC), 
adenocarcinoma (AC), large cell carcinoma (LC) and adenosquamous 
carcinoma (ADSCC), the lack of effective treatment against these different 
subtypes made sub-classification by pathologists less important.  
 
Over the past decade and a half however, there have been several 
advances with regards to targeted therapy against specific mutations in 
lung adenocarcinoma. These advances made it necessary for pathologists 
to accurately sub-classify lung cancer and submit tissue for mutational 
analysis. In order to accurately sub-classify lung cancer, well defined and 
uniform criteria and terminology was required. This led to the formation of 
an international panel of experts from the clinical, radiological, surgical and 
pathological disciplines. This panel provided a multidisciplinary approach to 
the histological diagnosis of lung AC and provided recommendations and 
guidelines for further mutational analysis in patients diagnosed with lung 
AC (Travis et al., 2011). Subsequently, the revised and updated version of 
the WHO classification of tumours of the Lung, Pleura and Heart by Travis 
et al. (2015) was published, which reflects these guidelines.  
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This version saw the terms “Non small cell carcinoma” (NSCC) and “Non 
small cell lung carcinoma (NSCLC)” being used interchangeably whilst the 
sub-classification of these carcinomas into AC, SCC, ADSCC and LC 
remained unchanged. There was also the introduction of the variant “NSCC 
not otherwise specified (nos.)”, which is a diagnosis made on small biopsy 
specimens when there are no clear morphological or immunohistochemical 
features of either an AC or SCC. The diagnosis of “NSCC, nos.” in a small 
biopsy is equivalent to the diagnosis of LC in a resection specimen. The 
last notable change was the replacement of tumours previously referred to 
as “Bronchioloalveolar carcinoma” with either “Adenocarcinoma with a 
lepidic pattern” if the tumour cells are non-mucinous or “Invasive mucinous 
adenocarcinoma” if the tumour cells are mucinous (Travis et al., 2015).  
 
2). Prognosis and treatment of lung cancer 
Worldwide, NSCC is the more common type of lung cancer and accounts 
for the high mortality rate associated with lung cancer (Herbst, Heymach 
and Lippman, 2008). The poor survival is attributed to late presentation. 
Nanguzgambo et al. (2011) found that 78% of patients from Cape Town 
presented with at least stage 3A (locally advanced) NSCC. This late 
presentation precludes surgery based therapy and until the late 1990s, the 
treatment of advanced lung cancer involved platinum-based chemotherapy 
regimens, irrespective of histological subtype (Pfister et al., 2004). Even 
with the use of third-generation cytotoxic drugs, the outlook was dismal as 
the increased response rate was found to be associated with an increased 
toxicity but no improvement in survival (Azim et al., 2009). In light of this, a 
search for a more effective method of treatment was undertaken. 
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3).Targeted therapy 
Advances in therapy have led to the development of molecularly targeted 
agents that inhibit specific pathways in tumour growth and progression, 
resulting in improved survival rates. It was shown in early studies from 
2004 and 2005 that patients with advanced NSCC, mainly AC, who showed 
an improved response following treatment with EGFR TKIs gefitinib and 
erlotinib, had lung cancer with the EGFR mutation (Lynch et al., Paez et al. 
and Pao et al., 2004 and Shepherd et al., 2005). The presence of the 
EGFR mutation was also found to be a prognostic factor independent of 
EGFR TKI treatment and patients with lung AC that had the EGFR 
mutation had improved response rates and prolonged survival, even when 
they received chemotherapy (Eberhard et al., 2005). In contrast, it was 
shown that lung cancers without the EGFR mutation responded better to 
conventional chemotherapy compared to EGFR TKI therapy (Mok et al., 
2009).  
 
The importance of these studies is twofold: they highlight the importance of 
accurately classifying lung cancer into its different types and subtypes and 
correctly identifying NSCCs that harbour the EGFR mutation and those that 
do not, in order to facilitate selection of the most appropriate therapy.  
 
4). Lung cancer trend: Squamous carcinoma versus adenocarcinoma 
The incidence of lung cancer in the world has increased from the 20th 
century onwards as a result of the increasing use of tobacco cigarettes. 
During the peak of this tobacco-related epidemic, SCC was found to be the 
most prevalent subtype of lung cancer (Travis et al., 2004). AC has been 
described in both smokers and non-smokers. Between 1965 and 2004, 
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cigarette smoking in adults in the United States decreased from 42% to 
21% because of legislated restrictions on tobacco products, resulting in a 
corresponding decrease in the number of SCC compared to AC. There was 
a suggestion that the increase in the number of AC was related to changes 
in smoking practices, such as deeper inhalation of cigarette smoke whilst 
cigarette design contributed as well (Devesa, Shaw and Blot, 1991; Wynder 
and Hoffmann, 1998 and Travis et al., 2004). AC is currently the more 
common subtype of lung cancer in developed countries (Ridge, McErlean 
and Ginsberg, 2013). 
  
There is limited published data on the prevalence of lung cancer from 
South Africa. Early literature published in 1990 by Willcox, O’Brien and 
Abratt found a higher prevalence of SCC in patients with lung cancer from 
Cape Town. This was similar to a study published in 2013 by Mukansi, 
Smith and Feldman et al., who looked at lung cancer patients admitted to 
hospitals in Johannesburg between 1992 and 1998. The shift in trend from 
SCC to AC as described internationally was however reflected in a study 
published in 2010 by Koegelenberg et al., where almost twice as many lung 
AC cases compared to SCC were found in the Western Cape.   
 
From the above, it appears that although there may be a shift in trend from 
SCC to AC in patients from the Cape, there may still be a higher 
prevalence of SCC in patients from Johannersburg. This research report 
may shed further light on which subtype of lung cancer is most prevalent in 
patients from Johannesburg.  
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5). Lung cancer mutations 
Lung cancer, like most cancers, is characterized by a number of genetic 
and epigenetic alterations that involve the activation of oncogenes and the 
inactivation of tumour suppressor genes (Figure 2.1, Modified from Cheng 
et al., 2012). The activation of oncogenes may occur through mutations 
(involving EGFR, KRAS, BRAF and ERBB2), translocations (involving ALK, 
ROS1 and RET) and amplifications (involving MET and FGFR1) (Travis et 
al., 2015). The activation of oncogenes occurs as a result of specific 
mutations called “driver mutations” whilst the inactivation of these 
mutations result in cancer cell death. The EGFR and Kirsten rat sarcoma 
(KRAS) mutations and the ALK translocation are driver mutations in lung 
cancer. 
According to Cheng et al. (2012) from data obtained from the Lung Cancer 
Mutation Consortium in the United States, approximately 64% of all AC 
cases harbour somatic driver mutations. 25% of ACs have mutations that 
involve the KRAS gene, 23% have mutations that involve the EGFR gene 
and 6% of cases harbour the ALK translocation, a transforming fusion gene 
product EML4–ALK. The mutation frequency of BRAF is 3%, PIK3CA 3%, 
MET amplifications 2%, ERBB2 (Her2/neu) 1%, MAP2K1 0.4%, and NRAS 
0.2%. Approximately 36.4% of lung adenocarcinomas do not harbour 
currently detectable mutations (Figure 2.1, Modified from Cheng et al., 
2012).  
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Most studies confirm that the oncogenic drivers for lung AC, i.e. mutations 
involving EGFR, K-RAS and ALK genes are mutually exclusive (Suzuki et 
al., 2006, Soda et al., 2007, Gandhi et al.,, Rodig et al., and Wong et al., 
2009 and Inamura et al., and Kwak et al., 2010) with the exception of 
isolated case studies by Boland et al. (2013) and Kadota et al. (2014).  
 
Pure SCC (without an AC component) do not harbour the EGFR, ALK and 
KRAS mutations (Rekhtman et al., and Heist et al., 2012).  SCLCs with the 
EGFR mutation were discovered to be combined SCLC with an AC 
component (Tatematsu et al., 2008).   
 
i). KRAS 
The most prevalent mutation found in lung AC involves the Kirsten rat 
sarcoma viral oncogene homolog (KRAS). KRAS mutations are seen in 
Unknown
KRAS
EGFR
EML4-ALK
BRAF
PIK3CA
MET
ERBB2
MAP2K1&NRAS
Figure 2.1 (Modified from Cheng et al., 2012): Frequency of major driver mutations in 
lung AC  
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approximately 25-30% of lung AC. It is an oncogene that encodes a 
GTPase downstream of EGFR.  Although more than 90% of KRAS mutated 
lung AC have a history of tobacco use, this mutation has been described in 
approximately 5% of non-smokers (Rodenhuis et al., 1987 and Lindeman 
et al., 2013). KRAS transversion mutations (GT or GC) are more 
common in former/current smokers whilst KRAS transition mutations 
(GA) are found in patients who have never smoked (Riely, Marks and 
Pao, 2009). Kadota et al. (2014) found that lung ACs with mucin (invasive 
mucinous AC and extracellular mucin) were more commonly associated 
with the KRAS mutation compared with non-mucinous ACs. 
 
Several recent studies, such as the study by Kim et al. (2012) including 
earlier studies by Massarelli et al. (2007) and Ladanyi and Pao (2008) have 
shown that patients with AC that have the KRAS mutation have a more 
than 96% chance of disease progression and its presence was an 
important predictor of poor response to EGFR TKI therapy. Furthermore, 
mutations in KRAS have been proposed to be one of the mechanisms of 
primary resistance to EGFR TKI therapy (Pao et al., 2005). An effective 
therapeutic agent against this mutation is not available although clinical 
trials using candidate drugs are currently underway. 
 
Testing for the KRAS mutation is recommended by Lindeman et al. (2013) 
only if adequate tissue is available for subsequent molecular (EGFR and 
ALK) analysis, if required.    
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ii). EGFR 
a) Background of EGFR 
The second most prevalent mutation, seen in approximately 18-30% of 
lung AC, involves the EGFR gene. EGFR was first reported on the cell 
membrane of fibroblasts by Carpenter et al. (1975) and has since been 
shown to be expressed in normal epithelium, mesenchyme and neurogenic 
tissue. EGFR belongs to the erbB family of receptor tyrosine kinases. 
These include erbB1 (also known as EGFR), erbB2 (Her2), erbB3 and 
erbB4. EGFR and its family of receptor tyrosine kinases are important in 
carcinogenesis as they modulate cell proliferation, apoptosis, cell motility 
and neovascularisation (Lynch et al., 2004, Paez et al., 2004, Gupta et al., 
2009, Bethune et al., 2010 and Inamura et al., 2010). EGFR undergoes a 
conformational change once it binds to a specific ligand, leading to 
downward signal transduction that, depending on the pathway, will result in 
cell proliferation, cell maintenance by inhibition of apoptosis, cell 
differentiation and motility. This occurs through auto activation of EGFR 
itself or through two downstream intermediate pathways that involve RAS 
and PIK3CA (Cheng et al., 2012).  
 
The Ras/Raf/MAPK pathway promotes cell proliferation and survival, while 
the PI3K/AKT pathway is associated with cell growth, inhibition of 
apoptosis, invasion and migration (Inamura et al., 2010). Early studies have 
shown that EGFR expression in NSCC is associated with reduced survival, 
frequent lymph node metastasis and poor chemosensitivity (Veale et al., 
1993, Fontanini et al., 1998). Inhibition of EGFR by TKIs is associated with 
an increase survival in patients with advanced NSCC (Shepherd et al., 
2005).  
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b) Genetic structure of EGFR 
The EGFR gene is 200kb and is found on chromosome 7p12. EGFR has 
an N-terminal extracellular ligand binding domain, a transmembrane 
lipophillic portion and a C-terminal intracellular region containing tyrosine 
kinase and regulatory domains. It comprises 28 exons and 27 introns. 
Exons 1 to 16 encode the extracellular domain, exon 17 encodes the 
transmembrane domain and exons 18 to 28 encode the intracellular 
domain.  
 
c) EGFR mutation, amplification and overexpression 
There are three types of EGFR alterations as described by Cheng et al. 
(2012) and Shepherd et al. (2005): namely mutation, copy number 
gain/amplification and protein overexpression.  
 
EGFR amplification, defined as more than five EGFR signals per nucleus, 
was found in 52% of EGFR mutant lung cancers and in only 6% of tumours 
without the EGFR mutation. Tumours with amplified EGFR had a solid 
growth pattern and were more aggressive (Bethune et al., 2010). Bethune 
et al. (2010) suggested that EGFR mutations occur as early events in 
carcinogenesis whilst gene amplification occurs later.  Even though 
patients with lung AC that have EGFR gene amplification may show  
improved survival following treatment with TKIs, EGFR gene amplification 
was less sensitive and specific and thus not suitable for determining which 
patients to select for EGFR TKI therapy. Approximately 50% of EGFR 
mutated cases have an increase in EGFR copy number whilst 75% of 
cases with an increased gene copy number have EGFR mutations (Li et 
al., 2008). This study supported findings by Ladanyi and Pao (2008).  Li et 
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al.’s study also showed that although overexpression of total EGFR (as 
detected using IHC) was found in 40-80% of lung tumours, it was not a 
successful prognostic marker and its presence was independent of the 
EGFR mutation.  
 
In summary, Ladanyi and Pao (2008) and Li et al. (2008) concluded that it 
was important to determine EGFR mutational status rather than EGFR 
amplification for the following reasons:  
1). Mutant EGFR is linked to ligand-independent increased downstream 
signalling, unlike simple overexpression of EGFR  
2). If both EGFR mutation and EGFR gene copy amplification are present, 
it is the mutant EGFR allele that is preferentially amplified, which suggests 
that it is the mutation that drives the selection for copy number gains  
3). EGFR mutation is more closely linked to risk factors (negative smoking 
history) and demographic features (Asian, female) compared to EGFR 
amplification 
4). Response rates of patients with EGFR mutation to EGFR TKI were 
high, irrespective of gene copy number whilst the response rates were low 
in the absence of the EGFR mutation 
5). EGFR mutation status was a better predictor of patient outcome in 
patients’ treatment with EGFR TKIs compared to EGFR copy number.  
 
Mutations in EGFR can occur in either the extracellular or intracellular 
domains of the protein but the majority show mutations in the intracellular 
tyrosine kinase domain (Paez et al., 2004).The tyrosine kinase domain is 
encoded by exons 18 to 24, whilst the C-terminal domain is encoded by 
exons 25 to 28.  More than 90% of the EGFR tyrosine kinase domain 
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mutations occur as short in-frame deletions in exon 19 (as the E746-A750 
15bp deletion) or as point (or missense) mutations in exon 21 (the latter 
results in arginine replacing leucine at codon 858 (L858R)) (Lynch et al., 
2004, Paez et al., 2004 and Pao et al., 2004). Less frequent mutations 
include point mutations (G719) in exon 18 and point mutations and in-frame 
insertions in exon 20. Although the most common deletion in exon 19 
includes the 15bp deletion (delE746-A750 and delL77-T751insS) and the 
18bp deletion (del747-P753insS), there are more than 20 other variants of 
the exon 19 deletion. These include deletion sizes of 9 base pairs (bp), 
12bp and 24bp. (Brevet, Arcila and Ladanyi, 2010 and Cheng et al., 2012). 
 
d) EGFR and lung cancer subtypes 
Numerous authors have reported on the prevalence of EGFR mutations in 
NSCC. The literature shows a much higher prevalence of EGFR mutations 
in AC compared to SCC. It has been suggested that SCCs that have the 
EGFR mutation may be ADSCC or a solid/ poorly differentiated AC with 
squamoid features (Rekhtman et al., 2012, Travis et al., 2011). 
Similarly, EGFR mutations have not been described in SCLC except in 
combined tumours where SCLC is combined with an AC component 
(Tatematsu et al., 2008). Other subtypes such as LC and NSCC (nos.) may 
also harbour this mutation as shown by Kim et al. (2012) in one of the 
largest studies that assessed the frequency of the three oncogenes EGFR, 
ALK and KRAS in patients with AC, SCC, LC and NSCC (nos.) who were 
never smokers. They concluded that the EGFR mutation was most frequent 
in patients with AC, followed by wild-type (no mutations), then the ALK 
translocation and lastly, the KRAS mutation. This study also confirmed that 
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most patients with SCC did not harbour any mutation (wild-type) and that 
the frequencies of the EGFR mutation and ALK translocation were equal in 
patients with LC whilst the frequencies of the EGFR and KRAS mutations 
were equal in patients with NSCC (nos.). 
 
e) EGFR and demographic profile  
A particular demographic profile for patients with EGFR mutated lung AC 
has been described. This includes patients who are young (mostly less 
than 65 years), female, never/non-smokers and of Asian ethnicity (Paez et 
al., 2004, Pao et al., 2004 and Shigematsu et al., 2005).  
 
Lung AC with the EGFR mutation was found to be more common in Asians 
compared to non-Asians. The prevalence of lung AC with EGFR mutations 
from patients who were from Asia, namely Korea, Taiwan, China and India 
was 24%, 51% and 38% and 26% respectively (Jang et al., 2009, Huang et 
al., 2011 and Doval et al., 2013) whilst studies from Europe and America, 
showed a lower prevalence of 11-19% (Rosell et al., 2009, Smits et al., 
2012, Cortes-Funes et al., 2005 and Reinersman et al., 2011).  
 
The degree of exposure to tobacco smoke was found to be inversely 
related to the presence of the EGFR mutation in patients with lung AC 
(Tokumo et al., 2005). Huang et al. (2011) found that significantly fewer 
EGFR mutations were found in patients who smoked more than 15 pack 
years. But although lung AC with the EGFR mutation was found to be more 
common in females and patients without a smoking history (Tokumo et al., 
2005, Rosell et al., 2009 and Kim et al., 2011,), these mutations were also 
found in some smokers and Korean males with AC (Sun et al., 2012). 
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Similar results were found in a South African study by Chan (2015) who 
showed smoking to be inversely proportional to the EGFR mutational status 
in a study population of 94 females and 75 males from Johannesburg.  
  
Several studies from different countries, namely Europe, North America 
and Asia, were reviewed by Lindeman et al. (2013) in an attempt to 
formulate molecular testing guidelines for lung cancer patients. The authors 
confirmed that lung cancer with the EGFR mutation was more common in 
females who were non-smokers. Similar demographic characteristics were 
found in patients who had lung cancer with the ALK translocation.  The 
recommendations made by Lindeman et al. (2013) state that when 
selecting patients for EGFR mutation and ALK translocation testing, 
patients should not be excluded based on their clinical characteristics such 
as age, sex, ethnicity and smoking history, despite the associations as 
noted above, as not all patients with the EGFR mutation and ALK 
translocation will fit into this demographic profile.    
 
Although there was no significant difference in the rate of the EGFR 
mutation in the African–American population (17%) compared to the 
American Caucasian population (13%) according to Reinersman et al. 
(2011), the KRAS mutation was found to be more prevalent in American 
Caucasians. This finding was not confirmed by Araujo et al. (2015), who 
found the rate of the EGFR and KRAS mutation similar in African-American 
and American Caucasians.  Chan (2015) found the EGFR mutational rate 
to be 61% in South African Caucasians and 19% in South African Blacks. 
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f) EGFR and morphological profile 
A specific morphological profile for lung ACs that have the EGFR mutation 
has been described and this includes ACs with a predominantly lepidic 
growth (previously called non-mucinous bronchioloalveolar carcinoma 
(BAC)) (Erman et al., 2005) and those with micropapillary and papillary 
growth patterns (Ninomiya et al., 2009 and Inamura et al., 2010). The 
hobnail cell type (characterized by cells that have cytoplasmic protrusions 
and a tadpole/hobnail appearance) was also found.  These characteristics, 
according to Ninomiya et al. (2009), may be used as good predictors of 
EGFR mutation in lung AC.  
 
Sun et al. (2012) on the other hand, revealed that EGFR mutations were 
more common in lung AC that had mixed patterns: mixed acinar and lepidic 
pattern, followed by a mixed papillary and acinar pattern, mixed solid and 
acinar, micropapillary and acinar patterns when compared to pure 
mucinous and solid tumours.  
 
In summary, the literature shows that although the lepidic, micropapillary 
and papillary growth patterns are seen in most lung cancers with the EGFR 
mutation, mixed growth patterns such as the acinar and solid patterns may 
be found.   
 
g) EGFR and EGFR TKI therapy 
An article entitled “update in lung cancer” published by Spira, Halmos and 
Powell (2015), states that it is well established that up front EGFR TKI 
therapy (gefitinib and erlotinib) supersedes the efficacy of platinum based 
chemotherapy and has become the current standard of care. Patients who 
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have the two most common EGFR mutations (E746-A750 deletion and the 
L858R point mutation) show a positive response rate between 48 and 90% 
following treatment with EGFR TKIs (Ilie et al., 2010).   
 
Treatment involves two options: the first option is preventing ligand binding 
to the extracellular domain using monoclonal antibodies and the second 
option is inhibition of intracellular tyrosine kinase activity by TKIs. The 
monoclonal antibody cetuximab targets the extracellular domain of EGFR, 
preventing ligand binding, blocking ligand-activated signal transduction and 
receptor dimerization. The limitation of this pathway is that since only ligand 
binding is inhibited, autophosphorylation of the tyrosine kinase domain 
through constitutive activation may still activate downstream pathways and 
promote carcinogenesis (Cheng et al., 2012).  
 
EGFR TKIs gefitinib (IRESSA®, Astra Zeneca UK) and erlotinib (Tarceva®, 
OSIL Genentech USA), bind the ATP-binding pocket of the intracellular 
domain, preventing autophosphorylation and intracellular downstream 
signalling (Ruschoff et al., 2013) and thus are more effective than the 
monoclonal antibody cetuximab.  
 
The European Medicines Agency (EMEA) supports the approval of gefitinib 
for patients with advanced and metastatic AC with the activating EGFR 
mutations (Ilie et al., 2010) whilst erlotinib is approved for the treatment of 
AC in Western countries (Eberhard, Giaccone and Johnson, 2008) 
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Careful selection of patients for gefitinib treatment is important as patients 
may be at risk of developing major clinical side effects such as acute lung 
damage and interstitial pneumonia (Inamura et al., 2010).   
 
EGFR TKIs are available in South Africa to a limited number of patients 
through private medical schemes. The majority of patients in South Africa 
who are attended to in Government hospitals do not receive EGFR TKI 
therapy as it is not on the Essential Drug List.   
 
h) Testing for the EGFR mutation 
There are several available methods for the detection of EGFR mutation. 
These methods include molecular and non-molecular 
(immunohistochemical) techniques. The molecular analyses include DNA 
sequencing and several indirect methods (see later). 
PCR is the most common method used to detect the presence of the EGFR 
mutation in lung AC (Angulo et al., 2012). Advantages of PCR include the 
ability to identify both common, uncommon and new activating EGFR 
mutations and the ability to identify mutations that may carry resistance to 
EGFR TKI therapy, such as the exon 20 EGFR insertion, the KRAS 
mutation which confers primary resistance and the T90M mutation for 
acquired resistance (Otto et al., 2012).  
 
The disadvantages of PCR are: 
1. It is an expensive procedure due to expensive tests and reagents 
 (NHLS cost as at 27/02/2017 = R634.41, value added tax inclusive) 
2. It is time consuming with a prolonged turnaround time 
3. It is not widely available in pathology laboratories 
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4. It is a complex procedure required specially trained personnel 
5. Its sensitivity depends on the  
a. quality of the extracted DNA   
b. tumour cellularity: mutation must be present in approximately 
20% of all the DNA in the sample to allow for adequate macro-
microdissection. The mutation may be missed if the sample contains 
<25% of tumour cells (Ladanyi and Pao, 2008) 
c. contamination of sample by non-neoplastic material such as 
mucin, lymphocytes, and non-neoplastic cells 
d. contamination with non-mutated allele   
e.  decalcification, which usually results in DNA degradation 
affecting mutation detection  
 
Most of the methods used in the literature are PCR based and perform best 
using fresh tissue instead of formalin fixed wax embedded tissue. Formalin 
fixation can lead to nucleic acid degradation and decreased amplicon 
length resulting in artefacts. PCR from formalin fixed wax embedded tissue 
requires a larger amount of tumour sample with a high ratio of tumour 
tissue to normal tissue content to reliably detect tumour-specific mutations. 
Macro or microdissection may be used to increase the ratio of tumour to 
normal tissue. This may not be possible on small biopsy samples such as 
endobronchial biopsies.   
Indirect methods include: 
a. High resolution melting analysis 
b. Fragment analysis 
c. Restriction fragment length polymorphism 
d. The amplification refractory mutation system 
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e. Mass spectrometry based MassArray platform 
f. Flourescence in situ hybridization (FISH) 
g. Chromogenic in situ hybridization (CISH)  
Indirect sequencing methods may have a higher sensitivity compared to 
direct sequencing and may therefore be used on specimens with low 
cellularity. These methods are very sophisticated, not readily available and 
require technical expertise (da Cunha Santos et al., 2011). FISH requires 
specialized equipment for dark field fluorescent microscopy and is limited to 
the detection of EGFR copy number and not the detection of specific 
mutations.  
 
In summary, there is a need for a method of detecting the EGFR mutation 
that is easy to perform and interpret, a method that requires minimal 
expertise and equipment, a method that provides results within a short time 
frame and a method that is available in most routine diagnostic pathology 
laboratories in South Africa that serve approximately 80% of the South 
African population. These criteria are fulfilled with immunohistochemistry 
(IHC).  
 
IHC is a method that localises antigens in tissue sections by using labelled 
antibodies. The antigen-antibody reaction is visualised by using markers 
such as florescent dyes, enzymes or colloidal gold. When antigen-antibody 
binding occurs, a coloured reaction is formed. This indicates a positive 
result with IHC (Eberhard, Giaconne and Johnson, 2008).  
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There are three types of immunohistochemical tests for EGFR: total EGFR, 
phosphorylated EGFR and mutation-specific EGFR. Only testing for the 
EGFR mutation using mutation specific antibodies is recommended.   
 
In 2009, Yu et al. were the first to develop two monoclonal antibodies 
against the two most common mutations involving the EGFR gene in lung 
AC, i.e. the SP111 antibody that detects the exon 19 15bp deletion E746-
A750 and the SP125 antibody that detects the exon 21 L858R point 
mutation, in New Zealand rabbits.    
 
IHC has the following advantages: 
1. It is used routinely in pathology laboratories 
2. Pathologists are familiar with interpretation of the IHC result 
3. It is less expensive than PCR (NHLS cost as at 27/02/2017 = 
R456.29, value added tax inclusive)   
4. It is a rapid procedure; results are available within 24 hours    
5. It can provide reliable results on limited material. Small biopsy and 
cytology specimens and metastatic tumours with too few malignant 
cells may prove technically challenging for micro or macro dissection 
which is required for molecular tests (Allo et al., 2014). Most patients 
with NSCC present late when surgery is precluded and thus most 
diagnoses of NSCC are made on small transbronchial and 
endobronchial biopsies. This limited material may be the only tissue 
available for diagnostic, prognostic and predictive testing. IHC, which 
requires the least amount of tumour tissue, may be very useful in this 
situation (Angulo et al., 2012).   
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6. It is reliable even if there is excessive non-neoplastic elements which 
may obscure the tumour  
7. Decalcification does not have any detrimental effect on IHC 
(Hasanovic et al., 2012).  
 
The main disadvantages of EGFR IHC are: 
1. Sensitivity and specificity of EGFR IHC compared to PCR. Mutation 
specific antibodies are specific for the two most common EGFR 
mutations only and do not detect other mutations in the EGFR gene 
(such as non 15bp deletions in exon 19, exon 18 G719 point  
mutation, exon 20 mutations and T790M resistance mutation).  
2. The absence of a universally accepted system of scoring positive IHC 
results. 
 
i) EGFR IHC sensitivity and specificity 
Numerous studies were undertaken to determine the reliability of the 
mutation specific antibodies SP111 and SP125 in detecting the most 
common EGFR mutations, the E746_A750 deletion in exon 19 and 
the L858R point mutation in exon 21 respectively, compared to PCR. 
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As seen in Table 2.1, almost all studies confirmed a high specificity of 90-
100% and a sensitivity which ranged from 61-100% for the SP111 and 
SP125 antibodies. The sensitivity of the SP111antibody was lower than the 
SP125 antibody.  
The findings of Seo et al. (2014) were supported by several similar studies 
undertaken by Kato et al. (2010), Kitamura et al (2010), Kozu et al. (2011), 
Hofman et al. (2012) and Hasanovic et al. (2012).  
The lower sensitivity found with the E746-A750 antibody in several of the 
above studies may be as a result of the presence of non-15bp deletions. 
The E746-A750 antibody detects mainly the 15bp deletion (which accounts 
for approximately 65-75% of deletions in exon 19 whilst it has a lower 
sensitivity in detecting non-15bp deletions (Brevet, Arcila and Ladanyi, 
2010).  
 SP111 SP125 
Sensitivity 
(%) 
61 (Ambrosini-Spaltro et al., 2012) 
63 (Simonetti et al., 2010) 
71 (Seo et al., 2014)  
82 (Kato et al., 2010) 
85 (Brevet, Arcila and Ladanyi, 
2010) 
75 (Kato) 
80 (Seo et al., 2014)  
95 (Brevet, Arcila and Ladanyi, 
2010) 
100 (Simonetti et al., 2010) 
100 (Ambrosini-Spaltro et al., 2012) 
Specificity 
(%) 
99 (Seo et al., 2014)  
99 (Brevet, Arcila and Ladanyi, 
2010) 
100 (Kato et al., 2010) 
100 (Simonetti et al., 2010) 
100 (Ambrosini-Spaltro et al., 2012) 
90 (Seo et al., 2014)  
97 (Kato et al., 2010) 
99 (Brevet, Arcila and Ladanyi, 
2010) 
100 (Simonetti et al., 2010) 
100 (Ambrosini-Spaltro et al., 2012) 
Table 2.1 Sensitivity and Specificity of mutation specific antibodies SP111 and SP125 
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j) Scoring for IHC stains with EGFR mutation specific antibodies 
A scoring system is used by pathologists when evaluating IHC stained 
slides, in order to assess staining intensity and distribution of positive 
stained cells.  
 
Correlation studies using IHC and molecular assays, as shown by 
Ambrosini-Spaltro et al. (2012) and Brevet, Arcila and Ladanyi (2010) 
showed a poor correlation with the presence of the EGFR mutation and 
0/1+ staining patterns. Only IHC scores of 2+ and 3+ correlated well with 
the presence of the EGFR mutation and were regarded as significant. By 
disregarding staining patterns of 1+ and only taking into account 2+ and 3+ 
staining patterns, the positive predictive values were raised to 100% with a 
minimal reduction in sensitivity. These results were confirmed by several 
additional studies which further confirmed the usefulness of mutation 
specific IHC as a screening method to detect patients for EGFR TKI 
therapy (Hasanovic et al., 2012 and Allo et al., 2014).  
 
While there is no universally accepted scoring system for assessing EGFR 
IHC, the following scoring system has been recommended by Ambrosini-
Spaltro et al. (2012), Hofman et al. (2012) and Seo et al. (2014): 
0: no staining/focal staining in <10% tumour cells 
1+: faint diffuse cytoplasmic staining in >10% tumour cells 
2+: moderate cytoplasmic staining with focal membranous reinforcement  
3+: strong cytoplasmic staining with focal or diffuse membranous 
reinforcement 
 
 
29 
 
k) Intratumoural heterogeneity 
Opinion is divided on whether intratumoural heterogeneity is significant and 
may affect testing for the EGFR mutation. Whilst Eberhard, Giaccone and 
Johnson (2008), Taillade et al. (2007) and Kitamura et al. (2010) found that 
intratumoral heterogeneity may account for false negative results with IHC 
and therefore suggest multiple biopsies from different areas of the tumour 
be taken, this was not supported by Sun et al. (2012) and not 
recommended by Lindeman et al. (2013).   
 
l) International recommendation 
Following a consensus meeting in 2013 with the College of American 
Pathologists, the International Association for the Study of Lung Cancer 
and the Association for Molecular Pathology, Lindeman et al. (2013) 
published guidelines for molecular testing of patients with lung cancer that 
have the EGFR mutation and ALK translocation as a step towards targeted 
therapy using Tyrosine Kinase Inhibitors.  
 
Although PCR is recommended for the detection of the EGFR mutation, 
Lindeman et al. (2013) state that if “scoring cut offs are set stringently to 
ensure a high positive predictive value, IHC with EGFR mutation-specific 
antibodies could be used as an initial screen to identify most patients who 
are candidates for EGFR inhibitors.” It is thus recommended that EGFR 
IHC be limited to a screening process. All negative biopsies should be 
referred for additional molecular analyses whilst strongly positive biopsies 
may be referred for EGFR TKI therapy. These recommendations were 
supported by several other studies (Ambrosini et al., 2012, Brevet, Arcila 
and Ladanyi, 2010 and Seo et al., 2014).  
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iii) Anaplastic lymphoma kinase gene (ALK) 
 
a) Background  
The third important genetic alteration seen in 2-7% of lung AC cases 
involves the Anaplastic Lymphoma Kinase (ALK) gene (Wong et al., 2009 
and Paik et al., 2012). ALK is expressed in the central and peripheral 
nervous systems, testes, skeletal muscle, basal keratinocytes and small 
intestine. ALK plays a role in neuronal development and differentiation 
during embryogenesis and its expression remains low throughout adult life 
(Shackelford et al., 2014). 
 
b) Genetic structure of ALK  
The ALK protein is a member of the insulin receptor superfamily of tyrosine 
kinase receptors and resides on chromosome 2p23. The ALK protein 
consists of an extracellular ligand-binding domain, a transmembrane 
domain and a single intracellular tyrosine kinase domain. 
 
c) ALK activation 
ALK activation occurs through three mechanisms: 1) formation of fusion 
proteins, 2) ALK over expression and 3) ALK point mutations. Morris et al. 
(1994) were the first to identify the NPM-ALK translocation in anaplastic 
non-Hodgkin lymphoma and since then, ALK translocations and mutations 
have been described in several tumours. Some solid tumours 
(inflammatory myofibroblastic tumours, squamous cell carcinomas and 
NSCCs) activate ALK signaling by creating unique oncogenic fusions of the 
ALK gene with a variety of partners through chromosomal translocation 
(Hallberg and Palmer, 2013). Up to 20 variants of the ALK translocation 
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have been identified (Shaw and Engelman, 2013). The most common 
fusion in NSCC results from the joining of exons 1-13 of echinoderm 
microtubule associated protein-like 4 (EML4) to exons 20-29 of ALK 
forming the EML4-ALK fusion gene.   
 
Soda et al. (2007) were one of the first to describe the ALK translocation 
resulting in the EML4-ALK fusion gene. This fusion gene product leads to 
dimerisation of the ALK tyrosine kinase domain and subsequent 
proliferation, changes in cytoskeleton, migration and survival of tumour 
cells (Shaw et al., 2011 and Soda et al., 2007 and 2013). 
 
The presence of the ALK translocation is mutually exclusive of EGFR and 
KRAS mutations, with the exception of individual case reports. In a study 
by Boland et al. (2013) which evaluated 25 cases of lung AC with the ALK 
translocation, a single case was also found to have the EGFR mutation and 
four cases had MET mutations.  
  
d) ALK and lung cancer subtypes 
The ALK translocation has been found predominantly in AC; however it has 
also been described in ADSCC and in a very small percentage of SCC 
(Wong et al., 2009, Rodig et al., 2009, Ali et al., 2013 and Paik et al., 
2012).   
 
e) ALK and demographic characteristics 
Numerous studies have shown a strong association of the ALK 
translocation with young patients and patients who were never smokers or 
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were light smokers (<10 pack years) (Inamura et al., 2010, Wong et al., 
2009, Paik et al., 2012 and Ali et al., 2013).   
 
There are conflicting results in the literature regarding sex; the majority of 
patients of Asian ethnicity appear to be female whilst Western countries 
including the United States of America (USA) show a predominance of 
males (Shaw et al., 2009).  Despite the presence of the ALK translocation 
in patients with certain demographic profiles as described above, Rodig et 
al. (2009) also found ALK rearranged tumours in older patients and patients 
with a smoking history. Wang et al. (2014) found that the ALK translocation 
in their study was not associated with non-smokers.  
 
In summary, demographic characteristics may therefore not necessarily 
accurately predict the presence of the ALK translocation and testing should 
not be restricted to patients based on their demographic characteristics. 
This is similar to the recommendations for testing for the EGFR mutation. 
 
When compared with the demographic characteristics of patients with lung 
cancer who have the EGFR mutation, the absence of a smoking history is 
the single consistent common characteristic, whilst ethnicity, sex and age 
are not.  
  
f) ALK and morphological profile 
Besides the above association with certain clinical characteristics, the ALK 
translocation has also been associated with certain AC morphological 
patterns; the most common includes the solid/sheet-like growth pattern 
(Rodig et al., 2009, McLeer-Florin et al., 2012 and Popat et al., 2012) whilst 
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the cribriform (McLeer-Florin et al., 2012), papillary (Hutarew et al., 2014), 
acinar (Wong et al., 2009, Hutarew et al., 2014) and lepidic (Yamamoto et 
al., 2012) patterns have also been described. Signet ring morphology also 
predominated in most of these studies, including the study by Zhang et al. 
(2014).  
 
Both EGFR mutated and ALK translocated ACs may have papillary growth 
patterns. The hobnail cell type is more commonly seen in lung ACs with the 
EGFR mutation whilst the signet ring cell type is more common in lung ACs 
that have the ALK translocation.   
 
g) ALK translocation prognosis and treatment 
The ALK translocation was not found to be a favourable prognostic factor 
and ALK positive patients have a generally poor outcome, similar to that of 
the general population of NSCC patients with advanced cancer (Shaw et 
al., 2011 and Shaw and Engelman, 2013). The presence of the ALK 
translocation is associated with increased lymph node metastasis (Paik et 
al., 2012). 
 
NSCCs with the ALK translocation are resistant to EGFR TKI (erlotinib and 
gefitinib) therapy (Shaw et al., 2009) but show an increased sensitivity to 
ALK TKI (crizotinib) therapy. Patients with lung AC who have the ALK 
translocation and are treated with crizotinib have an overall response rate 
of 57%. 72% of the patients treated were found to have a progression-free 
survival of more than 6 months and 92% of patients treated showed tumour 
shrinkage (Kwak et al., 2010).  
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Crizotinib is currently approved by the USA Food and Drug Administration 
(FDA) for use in patients with advanced NSCC with the ALK translocation 
and the use of this drug has been further supported by the 2013 guidelines 
of the American Society of Clinical Oncology (ASCO), the European 
Society for Medical Oncology and the National Comprehensive Cancer 
Network (NCCN) (Lindeman et al., 2013).  
 
Second generation ALK inhibitors (ceritinib and alectinib) showed similar 
results to the first generation ALK inhibitor (crizotinib) particularly regarding 
central nervous system (CNS) penetration. Most relapses on crizotinib 
occurred in the CNS (Spira, Halmos and Powell, 2015). 
 
h) Testing for the ALK translocation   
There are three methods available to detect the ALK translocation: 
fluorescence in situ hybridisation (FISH) assay using the dual labelled 
break apart probes, reverse transcriptase polymerase chain reaction (RT-
PCR) and IHC (Zhang et al., 2014 and Wang et al., 2013). 
  
FISH is used to detect chromosomal location and copy number of specific 
genes in tissue sections. This method uses fluorescence-tagged DNA 
probes that correspond to the gene to detect all cellular copies of the gene 
on tumour serial sections by fluorescence microscopy. FISH is the method 
that is being used in initial clinical trials to detect the ALK translocation and 
has been FDA approved for this purpose. The main advantage is the use of 
archival material for analysis.  
 
There are however many disadvantages with FISH analysis:  
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1. Interpretation of the result requires special skill as the signal may be 
subtle and easily missed leading to false negative results 
2. A minimum number of neoplastic cells is required to be present in the 
sample in order to yield a positive result that can be detected 
3. FISH does not allow one to differentiate neoplastic tissue from non-
neoplastic tissue so there may be uncertainty regarding the origin of 
the signal seen 
4. FISH requires dark-field fluorescence microscopy which is not routine 
equipment in a laboratory 
5. FISH has a longer turnaround time compared to IHC 
 
Although RT-PCR has been described by Wang et al. (2013) as the most 
sensitive method for the detection of the ALK translocation as it involves 
the use of unique primers that only hybridize with the specific fusion 
chimeric transcript, this method is not ideal as a screening tool as the 
specific fusion partners are unknown. The second main disadvantage is 
that RT-PCR requires high quality RNA, which may be difficult to obtain 
from wax embedded tissue, where the RNA is usually substantially 
degraded. It may also be difficult to confirm the presence of tumour cells in 
the PCR test sample (Murakami, Mitsudomi and Yatabe, 2012 and Wang et 
al., 2013). RT-PCR is not available in many routine pathology laboratories.  
 
Zhang et al. (2014) detected the ALK translocation by all three methods 
above and found the detection rate of IHC (35.7%) comparable to that of 
FISH (35.5%) and better than RT-PCR (27.9%).  
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IHC is widely available in NHLS Anatomical Pathology laboratories and is 
used as the preferred method for screening and diagnosis in routine 
pathology practices as discussed before. False negative results with ALK 
IHC were found to be highly dependent on the type of antibody clone and 
detection method used (Murakami, Mitsudomi and Yatabe, 2012). ALK IHC 
using high affinity antibodies and the use of an OtiView Amplification Kit 
greatly improved the sensitivity of the ALK IHC (Wallander et al., 2012, 
Hutarew et al., 2014 and Zwanepoel et al., 2014). ALK IHC using highly 
specific ALK antibodies has the added advantage of being able to detect 
complex ALK translocations which may be missed with RT-PCR and FISH, 
as shown by Mino-Kenudson et al. (2010) and Peled et al. (2012), 
respectively. 
 
Chromogenic in situ hybridization (CISH), which uses bright-field light 
microscopic techniques to assess gene copy number is an alternative to 
FISH and IHC. CISH is accurate and reproducible and has several 
advantages over FISH and IHC: 
1. CISH is easier to use because it uses bright-field microscopes 
instead of fluorescence microscopes which are more expensive 
2. CISH reagents are more stable than FISH reagents which fade over 
time preventing a sample from being examined more than once 
3. CISH does not require a high-resolution digital camera to capture 
micrographs of the sample before the fluorescence fades as with 
FISH 
4. CISH allows the tissue sample to be visualised, whilst FISH does not  
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5. IHC may have false-negative and false-positive results. The CISH 
reference probe will only be positive if the assay has worked. If there 
is no signal for the reference probe, the assay has failed 
 
A recent study by Nitta et al. (2013) showed promising results using Bright 
field dual ALK IHC-in situ hybridization assay. 
 
i) ALK IHC sensitivity and specificity compared with FISH  
There are several different ALK antibody clones. These include ALK1, 
ALK01, SP8 and high affinity clones, D5F3 (from Ventana OptiView) and 
5A4. Numerous authors have confirmed a much higher sensitivity of the 
high affinity clones compared to other clones. The high affinity clones 
stained ALK translocated cases with strong intensity without false positive 
or false negative cases (Wallander et al., 2012, Hutarew et al., 2014 and 
Zwanepoel et al., 2014). Similar studies by Boland et al. (2009), Paik et al. 
(2012), Minca et al. (2013), Shan et al. (2014) and Wang et al. (2014) 
confirmed 100% sensitivity with a specificity range of 95% to 100% using 
the high affinity ALK antibody clones with good correlation between ALK 
IHC and ALK FISH. 
 
Detection of the ALK translocation by ALK IHC using the high affinity 
antibody clones leads to a significant decrease in the number of cases 
referred for FISH analysis, resulting in a significant decrease in time, cost 
and work, without compromising diagnostic quality and accuracy.   
Based on these findings, we chose the high affinity D5F3 ALK antibody 
clone for this study.  
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j) Scoring of ALK immunohistochemical staining pattern 
The scoring system used for ALK IHC as determined by interpretation 
guidelines from Roche Ventana is based on the following criteria: 
0 = no cytoplasmic staining 
1+ = weak intensity cytoplasmic staining 
2+ = medium intensity cytoplasmic staining 
3+ = strong granular cytoplasmic staining 
In order to maintain a high degree of specificity and sensitivity, Roche 
Ventana recommend that biopsies showing 0, 1+ and 2+ staining be 
regarded as negative and only biopsies showing strong granular 
cytoplasmic staining be regarded as positive as they correlate well with 
ALK FISH.   
 
k) International recommendation 
The European Union has approved the use of IHC as a standard diagnostic 
test for ALK positive lung cancers and the Ventana ALK (D5F3) IHC assay 
has been approved to detect the ALK translocation in the European Union 
and some Asian countries (Reck et al., 2013).  
 
The general recommendation by numerous authors is to use ALK IHC as 
an initial screening method for the detection of the ALK translocation. There 
is good correlation with a 3+ IHC result and the presence of the ALK 
translocation whilst biopsies that show less intense staining may or may not 
have the translocation. Paik et al. (2012) showed that all 3+ biopsies were 
FISH positive, 65% of 2+ biopsies were FISH positive and all of the 1+ 
biopsies were FISH negative for the ALK translocation.  
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Based on this and similar studies, the recommendation by numerous 
authors (Lindeman et al., 2013, Cabillic et al., 2014, Selinger et al., 2013 
and Shan et al., 2014) is that cases that show a positive ALK IHC result be 
subjected to FISH analysis for confirmation of the ALK translocation 
although ALK immunohistochemistry may be considered as a screening 
methodology to select specimens for ALK FISH testing if carefully 
validated. Negative ALK IHC biopsies from patients with demographic 
characteristic or morphological features suggestive of the ALK translocation 
(such as never smokers with advanced lung AC or lung AC with signet ring 
morphology) and are found to be EGFR and KRAS wild type should be 
referred for ALK FISH analysis for the ALK translocation  (Selinger et al., 
2013).  Cabillic et al. (2014) concluded that this approach will have 
significant economic impact, with a shorter turnaround time compared to 
screening all patients with lung AC using ALK FISH.  
    iv) Other mutations 
Additional mutually exclusive oncogenes include Mesenchymal-epithelial 
transition factor (MET) tyrosine kinase and avian erythroblastosis oncogene 
B (ERBB2). MET overexpression, amplification and point mutation has 
been identified in NSCC. MET amplification is known to be associated with 
EGFR TKI therapy resistance (Spira, Halmos and Powell, 2015). Other 
mutations include BRAF, HER2, LKB1, P53, NRAS, PIK3CA and TTF1 
amplification (Herbst, Heymach and Lippman, 2008 and Greulich, 2010).   
 
v) Stepwise approach for mutational analysis   
An algorithmic approach towards mutational analysis of patients with lung 
cancer is suggested in Figure 2.2. The approach begins with exclusion of 
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the KRAS mutation, since this mutation is the most common mutation 
found in patients with lung AC and a positive KRAS result will preclude 
further mutational analysis (KRAS mutation is mutually exclusive of the 
EGFR mutation and ALK translocation). The use of a rapid and inexpensive 
KRAS assay is supported by Lindeman et al. (2013) provided adequate 
tissue is available to allow for subsequent EGFR and ALK testing if 
needed.  
 
Biopsies that are negative for the KRAS mutation will then be submitted for 
EGFR and ALK IHC. All strongly positive EGFR IHC biopsies may be 
forwarded for EGFR TKI (gefitinib or erlotinib) therapy whilst negative and 
weak to moderately positive EGFR IHC biopsies require EGFR PCR. 
Lindeman et al. (2013) recommend that all biopsies, even those showing 
positive staining with EGFR IHC be referred for EGFR PCR confirmation. 
They do however also state that IHC with EGFR mutation-specific 
antibodies may be used as an initial screen to identify patients who may be 
candidates for EGFR TKI therapy provided, “scoring cut offs are set 
stringently to ensure a high positive predictive value.” Seo et al. (2014) 
recommend direct referral for EGFR TKI therapy of these positive biopsies 
without PCR confirmation.  
 
All ALK IHC positive biopsies that show strong granular cytoplasmic 
staining may be forwarded for ALK TKI (crizotinib) therapy whilst weak to 
moderate positively stained biopsies and specific negative biopsies 
(biopsies from patients who have demographic features and ACs that have 
morphological patterns suggestive of the ALK mutation) need to be referred 
for ALK FISH analysis.  
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negative*, 
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Figure 2.2 Diagnostic algorithm for the mutational analysis of patients with lung cancer   
*Only ALK negative biopsies from patients with suggestive demographic characteristics & ACs 
with certain morphological patterns 
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Chapter 3: METHOD 
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3.2.2 Sampling technique 
3.3. Data collection and Materials  
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3.3.3 Data collection 
3.4 IHC 
 3.4.1 Slide preparation for IHC 
 3.4.2 EGFR and ALK IHC methodology 
 3.4.3 IHC analysis 
3.5 Ethics 
3.6 Statistical analysis 
 
Method 
3.1 Study type: Consecutive descriptive case series.  
3.2.1 Target population: All patients from CMJAH and HJH who had 
biopsies that were submitted to the pathology division of the NIOH, 
between the period of 1st January 2008 and 30th June 2014. 
3.2.2 Sampling technique: 
 Study setting: prior to August 2016 when the computerised TrakCare 
system was implemented, all histology case reports at the NIOH were 
filed together with the requisition and bronchoscopy reports. These 
cases did not receive SNOMED codes. Immunohistochemistry was 
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requested from the CMJAH NHLS laboratory when required, however 
a systematic approach for ordering IHC was not followed. The 
majority of specimens received at the laboratory were for diagnostic 
purposes and were therefore small specimens rather than resection 
specimens following curative surgery.        
 All biopsy reports received at the NIOH from 1st January 2008 until 
30th June 2014 were reviewed manually from the NIOH case report 
files.  
 Neoplastic reports were separated from non-neoplastic reports. 
 Neoplastic reports were then separated into AC, SCC, ADSCC, LC, 
NSCC (nos.), combined tumours (with an adenocarcinoma 
component), SCLC and “Other”. (Other= mesothelioma, sarcoma, 
lymphoma, salivary gland tumours, metastatic carcinomas, thymoma, 
hamartoma and cytology specimens).  
 
3.3.1 Reliability of data 
 The original diagnosis of lung AC, SCC, ADSCC, LC, NSCC (nos.), 
combined tumours (with an adenocarcinoma component) and SCLC 
were confirmed by reviewing the haematoxylin and eosin (H&E) 
sections, special stains and immunohistochemistry and by ordering 
additional immunohistochemistry where necessary, as determined 
using diagnostic criteria described in the 2015 WHO Tumours of the 
Lung, Pleura and Heart Classification (Travis et al., 2015) and 
classified into histological subtypes according to the International 
Association for the study of Lung Cancer/American Thoracic 
Society/European Respiratory Society (IASLC/ATS/ERS) (Travis et 
al., 2011) classification.   
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Lung cancer cases were sub-classified using the following criteria:  
AC = positive TTF1 and/or Napsin A staining of malignant cells, 
irrespective of P63 and CK5/6 staining 
SCC = malignant cells that show definite squamous differentiation, 
represented by intercellular bridges and/or cytoplasmic keratinization 
OR negative TTF1 and/or Napsin A staining with diffuse positive P63 
and/or CK5/6 staining 
ADSCC = a carcinoma comprising separate adenocarcinoma (confirmed 
with TTF1 positive and/or Napsin A positive malignant cells) and 
squamous carcinoma (P63 and/or CK5/6) components 
LC = a resection specimen with an undifferentiated carcinoma that 
shows negative TTF1 and/or Napsin A staining and negative P63 and/or 
CK5/6 staining of malignant cells  
NSCC (nos.) = a small biopsy (endobronchial/transbronchial/ 
transthoracic/ pleural) with an undifferentiated carcinoma that shows 
negative TTF1and/or Napsin A staining and negative P63 and/or CK5/6 
staining of malignant cells 
Combined tumour (with an AC component) = a biphasic lung cancer 
showing morphological and immunohistochemical characteristics of both 
Small cell lung cancer and lung AC  
SCLC = carcinoma with morphological characteristics of a small cell 
neuroendocrine carcinoma and positive staining with neuroendocrine 
markers 
AC with a lepidic growth = AC with a predominant lepidic growth AND 
positive TTF1 or Napsin A stain 
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3.3.2 Selection of cases  
 All biopsies with the diagnosis of AC, ADSCC, LC, NSCC (nos.) and 
combined tumours (with an adenocarcinoma component) were 
selected. SCC and SCLC biopsies were excluded. 
 The H&E stained slide of each of the selected cases were reviewed 
to ensure representation of malignant cells. Biopsies with very sparse 
representation of malignant cells (less than 5 cells per group or less 
than 5 isolated cells) were excluded. 
 Tissue blocks from each biopsy were retrieved. Biopsies with missing 
tissue blocks were excluded. 
 
3.3.3 Data collection 
 A data base sheet was prepared as follows: 
o Each case was allocated a study number beginning with 
biopsies selected from the 1st of January 2008 and ending with 
biopsies from the 30th June 2014 
o The original pathology number was retained 
o The demographic data i.e. race, age and sex obtained from the 
requisition form and /bronchoscopy report submitted with the 
specimen were recorded 
o The hospital that submitted the biopsy (CMJAH or HJH) was 
recorded 
o The biopsy type (transbronchial, endobronchial, transthoracic,  
open lung (wedge resection or lobectomy), pleural, lymph node 
or mediastinal) as indicated on the requisition form and 
/bronchoscopy report was recorded 
46 
 
o The smoking history was obtained from the requisition form and 
/bronchoscopy report. Medical records were accessed, where 
available, for cases without a smoking history  
o The pathological diagnosis (AC, ADSCC, LC, NSCC (nos.) or  
combined tumours (with an AC component) was recorded 
 
3.4.1 IHC slide preparation 
 5 recut sections at 4 microns were made from the tissue block of 
each case for the three IHC stains (EGFR SP111, EGFR SP125 and 
ALK D5F3) with 2 spare slides  
3.4.2 EGFR and ALK immunohistochemistry 
 Roche Ventana primary antibodies with the Ventana detection kits 
and a Ventana BenchMark XT and BenchMark ULTRA automated 
slide stainer were used, according to the manufacture’s protocol  
 IHC for the EGFR mutations included mutation specific antibodies 
that were the ready to use rabbit monoclonal anti EGFR E746-A750 
(clone SP111, Ventana Medical Systems, Inc.) and the anti-EGFR 
L858R antibodies (clone SP125, Ventana Medical Systems, Inc.).   
 4µm thick sections were cut and transferred to poly-l-lysine coated 
adhesive slides. The slides were baked on the Benchmark GX for 8 
minutes at 60°C. The slides were then deparaffinised using EZ Prep 
(Ventana Medical Systems, Inc.) at 75°C for 4 minutes. Heat antigen 
retrieval was performed using Ventana CC1 containing 
Tris/Borate/EDTA at pH 8-8.5. SP111 was incubated for 72 minutes 
and SP125 for 64 minutes. The antibodies were supplied as pre-
dilutes from Ventana and incubated at 37°C for 16 minutes (for 
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SP111) and 16 minutes (for SP125). Ultraview DAB detection kit was 
used for visualisation of the antibodies. 
 ALK D5F3 IHC for the ALK translocation (the EML4-ALK fusion 
protein) was purchased from Roche diagnostic laboratory. 
 For ALK (D5F3) immunohistochemistry, the sections were baked on 
the Benchmark GX for 12 minutes at 65 °C, then deparaffinised with 
EZ Prep from Ventana at 75 °C for 4 minutes. Heat antigen retrieval 
was applied on the sections using Ventana CC1 incubated for 92 
minutes at 100 °C. ALK (D5F3) was supplied pre-diluted from 
Ventana and incubated at 37 °C for 32 minutes. OptiView detection 
kit and amplification kit (Ventana /Roche) were used for visualisation 
of the antibody, to enhance the intensity of the staining and eliminate 
artefacts. The OptiView amplification kit builds a molecular tree with 
DAB chromogen bound to an amplification multimer that is linked to 
multiple haptens on top of the primary antibody. The signal intensity 
is thus stronger than conventional stained slides, without background 
staining. This allowed for strong clean signals, allowing confident 
identification of positive and negative samples, obviating the need for 
a subjective IHC scoring based on staining intensity and percentage 
of stained cells.  
 These tests were performed in the presence of appropriate positive 
and negative controls. Positive controls for the EGFR mutation were 
provided courtesy of Dr C Maske of Lancet laboratory on biopsies 
that were proven to harbor the respective mutation using PCR. A 
section of the appendix, courtesy of Mr A Lobanji of CMJAH NHLS 
laboratory, was used as a positive control for the ALK fusion protein 
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(Roche diagnostics recommend the use of positively stained neural 
tissue within the wall of the appendix as a positive ALK control).  
 Negative controls were provided by omission of the primary antibody 
and incubation with immunoglobulins of the same species.  
 
3.4.3 IHC analysis 
 EGFR SP111 and SP125: 
Scoring system as recommended by Ambrosini-Spaltro et al. (2012), 
Hofman et al. (2012) and Seo et al. (2014): 
0: no staining/focal staining in <10% tumour cells 
1+: faint diffuse cytoplasmic staining in >10% tumour cells 
2+: moderate cytoplasmic staining with focal membranous reinforcement  
3+: strong cytoplasmic staining with focal or diffuse membranous 
reinforcement 
Negative EGFR IHC= 0 and 1+; Positive EGFR IHC= 2+ and 3+ 
 ALK D5F3 IHC: 
Scoring as per guidelines by Roche Ventana:  
0 = no cytoplasmic staining 
1+ = weak intensity cytoplasmic staining 
2+ = medium intensity cytoplasmic staining 
3+ = strong granular cytoplasmic staining 
 The staining pattern (membranous and/or cytoplasmic) was recorded  
 The extent of the staining (patchy or diffuse) was recorded 
 The nature of the stain (granular or homogenous cytoplasmic) was 
recorded. 
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 The original H&E stained slide for all positive biopsies was reviewed 
and the morphological growth pattern (acinar/ lepidic/ papillary/ solid/ 
signet/ cribriform/ micropapillary) was recorded.  Carcinomas with 
mixed patterns were also recorded.  
 
3.5 Ethics 
Ethics clearance was received from the University of the Witwatersrand 
Human research ethics committee, clearance certificate no M140943 
(Annexure 9).   
 
3.6 Statistical analysis 
Data management and analysis were done using Stata version 14.1 
software.  Means and standard deviations were calculated to summarize 
the age variable by sex and outcome variable. A vertical graph box was 
drawn to describe the dispersion of age of the participants over the 
categories of the outcome variable (EGFR and ALK). The Student t-test 
with equal variances was used to test equality of age means between the 
negative and positive EGFR and ALK groups at 0.05 level of significance. 
The immediate two-sample proportion test, using EGFR and ALK as the 
group variable, was used to compare proportions of different levels of 
categorical variables between the negative and positive EGFR and ALK 
groups at 0.05 level of significance, and as such testing the hypothesis of 
equality of proportions. The two-sample proportion test was chosen 
because smoking status and race are categorical variables. A bivariate 
exact logistic regression was used to estimate odds ratios for factors 
associated with the EGFR and ALK variable. The exact logistic regression 
was chosen instead of the regular logistic regression because of the small 
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sample size of this study and because some of the cells formed by the 
outcome (EGFR and ALK ) and the independent variables sex, race and 
smoking history had no observations. P-values were generated to assess 
the significance of the association between the outcome and the covariates 
at 95% confidence level. 
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Chapter 4: RESULTS 
During the study period 3901 biopsies were received and after exclusion 
(see Figure 4.1), 111 biopsies were available for assessment of mutational 
status.   
 
• 3393 non neoplastic biopsies excluded 
3901 Total biopsies  
• 37 (7%) neoplastic biopsies were reclassified as AC, SCC, 
ADSCC, LC, NSCC (nos.) or possible metastatic carcinoma 
(Annexure 2 and 3) 
• 211 neoplastic biopsies referred to as "other" (mesothelioma, 
sarcoma, lymphoma, salivary glands tumours, metastatic 
carcinomas, thymoma, hamartoma and cytology specimens) 
were excluded   
508 Neoplastic biopsies  
• 165 lung cancer biopsies diagnosed as SCC (128), SCLC (36), 
Combined SCLC (1) were excluded 
• (The combined SCLC was a combined SCLC and large cell 
neuroendocrine carcinoma) 
297 Lung Cancer biopsies 
•  The following biopsies were excluded 
• 4 AC biopsies with a lepidic growth with negative TTF1 +/or 
Napsin A stains 
• 2 biopsies that were duplicate biopsies from the two patients 
• 7 biopsies did not have available tissue or tissue block  
 
132 NSCC  
• 119 biopsies were stained with the EGFR and ALK IHC stains 
• 8 biopsies were excluded as tissue and/tumour were not present 
on the slides after IHC  
119 NSCC (107 AC, 4 ADSCC, 7 NSCC (nos.), 1 LC  
111 biopsies available for mutational analysis 
Figure 4.1 Vertical flow diagram on selection of cases for EGFR and ALK IHC      
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Of all 119 patients with NSCC, most patients were Black (61%) and males 
(61%). There were no Asians. Adenocarcinoma comprised 90% of the 
histological subtype (Table 4.1). 
Table 4.1 Demographic data, biopsy type, smoking and occupational history on 119 
NSCC biopsies 
 (n) (Total 119) (%) 
Hospital 
CMJAH 
HJH 
 
86 
33 
 
72 
28 
Race 
Black 
White 
Other (coloured) 
 
72 
35 
12 
 
61 
29 
10 
Sex 
Male 
Female 
 
72 
47 
 
61 
39 
Age 
< 65 years 
> 65 years 
mean 57 (SD 11.5) 
91  
27 
 
77 
23 
Biopsy type 
Small biopsies*  
Large biopsies** 
Pleural biopsies 
Lymph node biopsies  
 
75 
9 
33 
2 
 
63 
8 
28 
2 
Occupational history 
Not available 
Miner^ 
Other^^ and Non-miner 
 
107 
8 
4 
 
90 
7 
3 
Smoking history 
Not available  
ExSmoker 
Smoker 
Non-smoker 
 
18 
6 
71 
24 
 
15 
5 
60 
20 
Biopsy diagnosis 
AC 
ADSCC 
LC  
NSCC (nos.) 
 
107 
4 
1 
7 
 
90 
3 
1 
6 
*Small biopsies = endobronchial biopsies (52) and transbronchial biopsies (12), 
transthoracic core biopsies (9) and mediastinal biopsies (2). **Large biopsies = wedge 
resections (6) and lobectomy (3). ^Miner = asbestos (2), platinum (2), coal (1), gold (1), 
commodity unknown (2). ^^Other = Flour mill worker  
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Of the 111 biopsies available for testing, there were 10 biopsies (9%) that 
showed positive staining with the EGFR IHC and 8 biopsies (7%) that 
showed positive staining with the ALK IHC (Table 4.2). All biopsies that 
showed positive staining with the EGFR and ALK IHC were 
adenocarcinomas. None of the other NSCC subtypes showed positive 
staining, although the number of biopsies in each of the other subtypes was 
small.  
 
Table 4.2 Mutational status by lung cancer type 
Lung cancer 
type 
EGFR 
SP111 
+ n(%) 
EGFR 
SP111 
- n(%) 
EGFR 
SP125 
+ n(%) 
EGFR 
SP125 
- n(%) 
EGFR 
Total  
+ n(%) 
EGFR 
Total 
- n(%) 
ALK  
+n(%) 
ALK  
-n(%) 
AC  8(8) 92(92) 2(2) 100(98) 10(10) 90(90) 8(8) 92(92)  
ADSCC 0 4 0 4  4 0 4 
LC 0 2 0 2  2 0 2 
NSCC (nos.) 0 5 0 5  5 0 5 
Total n(%) 
 
8(7) 
 
103(93)  2(2)  
 
111(98)  
 
9(10) 101(91) 8(7) 103(93) 
 
The majority of biopsies were from male patients (63.06%) who were Black 
(60.06%) (Figure 4.2). The mean age was 56.84 ± 9.75 years among 
males and 58.71 ± 10.88 years among females. 67.57% of the participants 
had a positive history of smoking while 13.5% did not have any smoking 
information available.  
Refer to Annexure 4a and 4b for details on the demographic data, smoking 
history and occupational history of biopsies showing positive staining with 
EGFR and ALK IHC and Annexure 5, histogram showing the parametric 
distribution of age for EGFR and ALK analysis. 
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Figure 4.2 Frequency distribution of biopsies for EGFR and ALK IHC by sex and race 
 
EGFR IHC analysis  
As shown in Table 4.3, no significant difference between mean age among 
biopsies that had positive and negative EGFR IHC results was found 
(student t-test, p= 0.83). Table 4.4 shows the association between the 
EGFR IHC and the demographic characteristics of patients, smoking 
history and occupational history. Ten biopsies had a positive EGFR IHC 
result (9.05%), eight of them were from Black patients. Of the biopsies from 
patients with a smoking history, 5.33% had a positive EGFR IHC result 
(two-sample proportion test, p= 0.051). However this association with 
smoking was not found to be statistically significant when an adjustment for 
the other features (age, sex and race) was made (odds ratio 1.553, p= 
0.378) (Table 4.5). Occupational history was not included in the regression 
model because of the high number of missing values (100 of 111). A single 
patient with a positive gold mining history was found to be EGFR IHC 
positive whilst the two patients with asbestos exposure were not EGFR IHC 
positive.    
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Table 4.3 Relationship between age, sex and EGFR IHC result 
 Male Female  Total 
EGFR 
test 
n mean SD min max n mean SD min max N mean SD min max 
Negative  64 56.73 9.68 38 76 37 58.73 11.23 28 78 101 57.47 10.27 28 78 
Positive  6 58 11.37 36 67 4 58.5 7.94 48 67 10 58.20 9.64 36 67 
Total 70 56.84 9.75 36 76 41 58.71 10.88 28 78 111 57.54 10.18 28 78 
 
Table 4.4 Association between EGFR IHC, demographic characteristics, smoking 
history and occupational history 
Characteristics 
  
EGFR 
Negative 
n(%) 
EGFR 
Positive 
n(%) 
Total 
n(%) 
Biopsies 101(90.99) 10(9.01) 111(100) 
Age mean (SD) 57.47 (9.78) 58.2 (9.64) 57.54(10.18) 
Sex 
Male 64 (91.43) 6(8.57) 70(100) 
Female 37 (90.24) 4(9.76) 41(100) 
Race 
Black 59(88.06) 8(11.94) 67(100) 
White 33(97.06) 1(2.94) 34(100) 
Other 9(90) 1(10) 10(100) 
Smoking 
History 
Smoker 71(94.67) 4(5.33) 75(100) 
Non-smoker 16(76.19) 5(23.81) 21(100) 
Unknown 14(93.33) 1(6.67) 15(100) 
Occupational 
History 
Not available 91(91.00) 9(9.00) 100(100) 
Miner (nos.) 2(100) 0 2(100) 
Non-miner 2(100) 0 2(100) 
Asbestos exposure 2(100) 0 2(100) 
Platinum miner 2(100) 0 2(100) 
Flour mill worker 1(100) 0 1(100) 
Gold miner 0 1(100) 1(100) 
Coal miner 1(100) 0 1(100) 
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Table 4.5 Bivariate exact logistic regression of features associated with EGFR IHC 
Independent variable  odds ratio p-value 95% confidence interval 
Age 1.007 0.856 0.945 1.077 
Sex 1.152 1.000 0.224 5.223 
Smoking History 1.553 0.378 0.61 3.652 
Race 0.57 0.513 0.111 1.883 
Occupational History 1.162 0.5303 0.664 1.729 
 
 
ALK IHC analysis 
The mean age of the patients tested for ALK IHC was 56.91 ± 9.81 years 
among males and 58.81 ± 10.76 years among females (Table 4.6). The 
difference between mean age among biopsies that had positive and 
negative ALK IHC results was not significant (student t-test, p= 0.071) 
(Table 4.7). Among these, 50% of patients had a history of smoking, 
although there were no significant difference in the proportions of smokers 
among those who tested positive to ALK and those who tested negative. 
Nevertheless, there was significant difference between the proportions of 
Black patients among those who tested positive to ALK and those who 
tested negative (two-sample proportion test, p= 0.017) even when race was 
corrected against the other features (sex, age and smoking history) (odds 
ratio 0.155, p= 0.03) (Table 4.8). The regression model confirms the 
association between age and ALK IHC (odds ratio 0.941, p= 0.081), which 
is not significant.  Occupational history was not included in the regression 
model because of the high number of missing values (100 out 111). The 
two biopsies from patients with asbestos exposure were not ALK IHC 
positive.    
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Table 4.6 Summary measures of age by ALK IHC and sex 
 Male Female  Total 
ALK test n mean SD min ma
x 
n mean SD min max N mean SD min max 
Negative  63 57.08 9.72 36 76 40 59.75 9.77 30 78 103 58.13 9.78 30 78 
Positive  6 55.17 11.48 41 71 2 40 16.97 28 52 8 51.38 13.59 28 71 
Total 69 56.91 9.81 36 76 42 58.81 10.76 28 78 111 57.64 10.18 28 78 
 
Table 4.7 Association between ALK IHC, demographic characteristics, smoking history 
and occupational history 
Characteristics 
  
ALK Negative 
n(%) 
ALK 
Positive 
n(%) 
Total 
n(%) 
Biopsies 103(92.79) 8(7.21) 111(100) 
Age mean (SD) 58.13 (9.78) 
51.38 
(13.59) 57.64(10.18) 
Sex 
Male 63 (91.3) 6(8.7) 69(100) 
Female 40 (95.24) 2(4.76) 42(100) 
Race 
Black 59(88.06) 8(11.94) 67(100) 
White 34(100) 0 34(100) 
Other 10(100) 0 10(100) 
Smoking 
History 
Smoker 70(94.59) 4(5.41) 74(100) 
Non-smoker 20(90.91) 2(9.09) 22(100) 
Unknown 13(86.67) 2(13.33) 15(100) 
Occupational 
History 
Not available 92(92.93) 7(7.07) 99(100) 
Miner (nos.) 2(100) 0 2(100) 
Non-miner 3(100) 0 3(100) 
Asbestos exposure 2(100) 0 2(100) 
Platinum miner 2(100) 0 2(100) 
Flour mill worker 0 1(100) 1(100) 
Gold miner 1(100) 0 1(100) 
Coal miner 1(100) 0 1(100) 
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Table 4.8 Bivariate exact logistic regression of features associated with ALK IHC 
Independent variable  Odds Ratio P-value 95% Conf. Interval 
Age 0.941 0.081 0.876 1.008 
Sex 0.528 0.711 0.05 3.141 
Smoking History 1.642 0.371 0.583 4.244 
Race 0.155 0.03 0 0.866 
OH 1.159 0.546 0.327 1.763 
 
The acinar morphological growth pattern was the most common pattern 
found in the EGFR IHC positive biopsies (Table 4.9 and Figure 4.3 (A)). 
Hobnail cells were not a feature in biopsies that showed positive staining 
with the EGFR IHC. The acinar and lepidic patterns were equally found in 
the ALK IHC positive biopsies. Only a single ALK positive biopsy contained 
cells with a signet ring morphology (Table 4.9).  
 
Table 4.9: Morphological patterns of lung ACs with positive EGFR and ALK IHC 
Morphological pattern EGFR IHC   
(n)                    % 
ALK IHC 
(n)                     % 
Acinar 8 80 3 38 
Lepidic 1* 10 1** 13 
Solid 1 10 3** 38 
Papillary 0  1** 13 
Micropapillary 1* 10 1 13 
Signet ring cells 0 0 1 13 
Total  10  8  
* the same tumour showed a mixed lepidic and micropapillary pattern 
** the same tumour showed a mixed solid, lepidic and papillary pattern 
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Figure 4.3 Morphological growth patterns in EGFR and ALK IHC positive lung 
adenocarcinomas (Haematoxylin and Eosin stained sections at 10X magnification). 
(A), Acinar. (B), Cribriform. (C), Micropapillary. (D), Papillary. (E), Solid. (F), Lepidic 
 
All EGFR IHC positive biopsies showed strong cytoplasmic staining with at 
least focal membranous reinforcement (Figure 4.4 (A), whilst biopsies that 
A 
F 
D C 
E 
B 
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showed positive ALK IHC showed strong granular cytoplasmic staining 
(Figure 4.4 (B)). Refer to Annexures 6 and 7. 
 
Figure 4.4 Immunohistochemical staining patterns using mutation specific EGFR 
antibody and High affinity ALK antibody (D5F3) at 20X magnification. (A), EGFR IHC 
positive case with diffuse homogenous cytoplasmic staining and focal membranous 
staining (arrow). (B), ALK IHC positive case with diffuse granular cytoplasmic staining 
 
SCC is the more common overall subtype of lung cancer (46%) compared 
to AC (39%) in this group of patients from Johannesburg. 
 
Figure 4.5 Lung cancer trend over six and a half years in patients from Johannesburg 
Hospital (Charlotte Maxeke Johannesburg Academic Hospital/ CMJAH and Helen 
Joseph Hospital/HJH) 
 
 
A B 
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Chapter 5: DISCUSSION 
 
According to Lindeman et al. (2013), guidelines from the College of 
American Pathologists, the International Association for the Study of Lung 
Cancer and the Association for Molecular Pathology, recommend that 
EGFR and ALK testing be undertaken on all ACs and mixed lung cancers 
with an AC component, regardless of histologic grade. This includes LCs in 
resection specimens, NSCCs in small biopsy specimens and combined 
carcinomas with an AC component.  
 
The EGFR mutation 
More than 90% of EGFR mutations occur as short in frame deletions in 
exon 19 (as detected using the EGFR 111 antibody) or as point mutations 
in exon 21 (as detected using the EGFR 125 antibody) and testing for the 
presence of both mutations is necessary.  
 
The EGFR mutation rate in this study is 9%, which correlates with a study 
of French patients by McLeer-Florin et al (2012) but is significantly less 
than the 24-51% incidence described in literature from Eastern countries 
(Korea, Taiwan, China and India) (Jang et al., 2009, Huang et al., 2011, 
Doval et al., 2013) and less than the 11-19% incidence described in 
literature from Europe and America (Cortes-Funes et al., 2005, Rosell et 
al., 2009 and Smits et al., 2012).  
 
This EGFR mutation rate of 9% is also less than the 21.8% found by Chan 
(2015) in a study of 76 lung cancer patients from Johannesburg. There are 
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several reasons that may account for the discrepancies in the EGFR 
mutational rate between the two South African studies. Although Chan’s 
study (2015) was also based on patients from Johannesburg, they were 
demographically different. Selection bias in Chan’s study may have played 
a role as the patients selected for EGFR mutational analysis were 
predominantly White (71%) females who were never smokers or former 
light smokers, who were referred from private medical facilities. Patients in 
the current study are patients who presented to Government hospitals in 
Johannesburg and were diagnosed with lung cancer on biopsy specimens 
sent to the NIOH pathology division. These biopsies were from 
predominantly Black male patients who had a strong smoking history. The 
demographic profile of patients with lung cancer in this report is 
representative of the demographic profile of patients with lung cancer in 
South Africa (Ferlay et al., 2012). The results in this study may therefore be 
more reflective of the mutational status of the South African population 
compared to the previous study by Chan (2015).  
 
The EGFR IHC mutation rate of 9% is however also lower than the EGFR 
mutation rate of 22.6% found in the subgroup of Black patients in Chan’s 
study (2015). There may thus be additional reasons responsible for the 
lower mutational rate observed.  
 
The most significant difference with most of the published literature 
including Chan’s (2015) is the use of EGFR PCR, which is a more sensitive 
method for the detection of the EGFR mutation, instead of EGFR IHC. 
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Added to this, certain factors may have affected the reliability of the IHC 
result, as described by Atkins et al. (2004) and Eberhard and Ladanyi 
(2008). These include appropriate fixative medium and duration of fixation 
of specimens, time from when the slide is prepared from the tissue block to 
when the stains are applied, antigen retrieval techniques, antibody 
detection protocols and the size and quality of the tissue sections used.  
Although the recommended fixation time for optimal EGFR expression is 
between 8 and 24 hours in 10% neutral-buffered formalin, we do not have 
control over the time it takes for specimens in formalin to reach the 
laboratory. There may be delays of between 24 and 48 hours before a 
specimen is received. Antigen retrieval may be affected by prolonged 
storage of unstained recut slides due to a time-dependent loss of 
immunoreactivity from antigen degradation. This may be seen in slides that 
were stored even for just 3 months. We experienced unforeseen delays in 
performing the IHC tests once slides were cut which may have affected 
antigen integrity. Tissue blocks were not recut as the majority of biopsies 
received were small specimens that had minimal tissue available and for 
cost implications. Intratumoral heterogeneity may have also contributed to 
false negative results, as shown by Kitamura et al. (2010) and as most 
biopsies received at the NIOH pathology division are small specimens 
rather than resection specimens, we cannot exclude that there may have 
been areas within the tumour that were not represented on the biopsy that 
may have had the EGFR mutation. 
 
There were no Asians in our study population. The majority of patients 
whose biopsies showed positive EGFR IHC, were Black (80%), male (60%) 
patients who are younger than 65 years of age (80%). The association 
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between age, sex, race and the EGFR mutation as detected by EGFR IHC 
was however not statistically significant. A statistically significant 
association (p= 0.051) was found in biopsies from patients who had a 
smoking history and a positive EGFR IHC result. Although this is an 
unusual finding as the majority of studies have shown an association with 
non-smokers (Cheng et al. 2012), it does reflect the findings of a study of 
Korean patients by Sun et al. in 2012. The high percentage of smokers in 
the study population (67.57%) may have contributed. These results 
suggest that smoking may have a stronger association with the EGFR 
mutation in South African patients in contrast with patients from Asia, 
Europe and America.  It should however be noted that when smoking was 
corrected with other features (age, race and sex), the association was no 
longer found significant. The small number of biopsies may have 
contributed to this.  
 
In order to ensure reliability of the interpretation of the EGFR 
immunohistochemical stains used, we adhered to guidelines outlined by 
Brevet, Arcila and Ladanyi (2010), Ambrosini-Spaltro et al. (2012), 
Hasanivic et al. (2012) and Allo et al. (2014). These authors confirm good 
correlation between EGFR IHC positive results and the presence of the 
EGFR mutation if these guidelines are adhered to.  
 
Although a range of morphological growth patterns of EGFR positive lung 
ACs were represented in this study, a dominant morphological growth 
pattern was not observed.   
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The findings in this report support the international recommendation that 
the demographic profile of patients and the morphological features of the 
tumour should not dictate whether a patient’s biopsy is submitted for EGFR 
mutational analysis (Lindeman et al., 2013). 
 
The ALK translocation 
The ALK translocation rate is 7%. This is the upper limit of most recorded 
literature, which ranges between 2 and 7% (Wong et al., 2009 and Paik et 
al., 2012). The high affinity ALK IHC antibody, D5F3, has a high sensitivity 
and specificity when compared with ALK FISH for the detection of the ALK 
translocation (Hutarew et al., 2012) and the results of this study supports 
the sensitivity of the ALK IHC in detecting the ALK translocation. A positive 
result of 7% suggests that the ALK translocation may be more prevalent in 
patients with lung AC from South Africa than other countries. 
 
The demographic characteristics of patients whose biopsies showed 
positive staining with the ALK IHC is similar to those showing positive 
staining with EGFR IHC, i.e Black (100%) males (75%) younger than 65 
years of age (88%). The majority of patients with lung cancer in this study 
were Black and a statistically significant association between race and the 
ALK mutation (p= 0.017) was found. There is an association with younger 
patients and positive ALK IHC, but this was not found to be statistically 
significant (p= 0.081).  
 
The predominantly acinar and solid growth patterns observed in the ALK 
IHC positive biopsies is in line with the patterns described by Travis et al., 
(2015). The signet ring morphology however cannot be used as a 
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determinant of the ALK mutation as it is present in only a single ALK IHC 
positive biopsy. Most of the biopsies received were small biopsy specimens 
and accurate identification of the morphological growth pattern was not 
always possible.  
 
In view of the findings of this study, we re-evaluated the suggested 
algorithm on page 41 and recommend that in the absence of adequate 
tissue; molecular analysis be restricted to EGFR and ALK analysis. We 
recommend that patients with biopsies that show strong (3+) positive 
EGFR IHC staining be referred for EGFR TKI therapy whilst less positive 
staining and negative biopsies be subjected to PCR to assess for the 
presence of the EGFR mutation. Similarly, patients with biopsies that show 
strong (3+) positive ALK IHC staining be referred for ALK TKI therapy 
whilst equivocal biopsies that show less strongly positive staining be 
subjected to FISH. ALK IHC negative biopsies do not need additional 
mutational analyses unless the patient is young (less than 65 years old), 
with a non-smoking history or the biopsy has a predominantly acinar or 
solid growth pattern with signet ring cells.    
 
Updated guidelines for sub-classifying lung cancer   
7% of lung cancer biopsies that were diagnosed prior to the publishing of 
the latest WHO classification for lung cancer (Travis et al. 2015) were 
reclassified. These guidelines therefore assure that a correct final diagnosis 
can be made by following a standard protocol for lung cancer diagnosis, 
using morphological features and immunohistochemistry.  
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Lung cancer trend in South Africa 
Smoking remains a significant contributor to the incidence of lung cancer in 
South Africa despite anti-tobacco measures taken by the Department of 
Health and The National Council against Smoking. The significance of 
smoking is reflected in the results of this research report, which shows that 
60% of patients diagnosed with lung AC, ADSCC, LC or NSCC (nos.) were 
smokers and SCC remains the more common subtype of lung cancer. The 
shift in trend towards AC in lung cancer as seen internationally and in 
patients from Cape Town is not observed in this study of patients from 
Johannesburg. Greater effort therefore needs to be made to reduce 
tobacco smoking and the burden of lung cancer.   
 
Limitations: 
The limitations of the study are the following: 
1). The number of lung cancer biopsy samples that were available in this 
study for immunohistochemical analysis was small compared with most 
international literature. Chan’s study comprised 170 biopsies from patients 
who had clinical features suggestive of the EGFR mutation, with a yield of 
37 positive cases (21.8%).  Even though exact logistic regression was 
chosen instead of the regular logistic regression, no significant correlation 
was found with most of the features.    
2). The delay between cutting of the slides and the actual application of the 
IHC antibodies may have compromised epitope preservation and integrity, 
contributing to false negative IHC results. 
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3). Smoking history was not available for all cases. The association 
between smoking and the ALK mutation was affected by the absence of a 
complete smoking history for all ALK positive biopsies.  
4). Occupational history was not available for the majority of cases. The 
association between asbestos fibre exposure and the EGFR mutation and 
ALK translocation could not be assessed.  
5). EGFR and ALK IHC were only performed on lung cancers that were 
diagnosed as AC, ADSCC, LC and NSCC (nos.). Most biopsies received 
were small biopsy specimens (63%) instead of resection specimens. The 
yield of positively stained cases may have been higher if EGFR and ALK 
IHC had been applied to all lung cancers, even those diagnosed as pure 
SCC or SCLC, provided certain suggestive clinical features such as young 
age and a non-smoking history were present. This is the recommendation 
by Lindeman et al. (2013) which is based on the presence of tumour 
heterogeneity that may not be reflected on a small biopsy specimen. 
However, resource constraints prevented us from assessing all lung 
cancers and the tests were confined to the specific subtypes as noted 
above.     
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Chapter 6: CONCLUSION 
 
Although targeted therapy for patients with lung cancer that have the EGFR 
mutation and ALK translocation is only available in South Africa at present 
in the clinical trial setting and for some patients in the private sector, it is 
envisaged that this method of treatment may become more readily 
available and be part of the standard treatment regimen for patients with 
advanced NSCC in the future.  
 
This study confirms the presence of the EGFR mutation and ALK 
translocation in patients with AC from Johannesburg using IHC.  
 
We have modified the proposed algorithmic approach for the mutational 
analysis of patients with lung cancer in a resource constrained country 
such as South Africa, where EGFR and ALK IHC performed on limited 
biopsy material is used as rapid initial screening tests to identify patients 
with the EGFR mutation and ALK translocation, provided appropriate 
guidelines for IHC interpretation are adhered to (Figure 2.2). IHC tests are 
more cost effective than molecular analysis with a saving of 28% per 
patient at current tariff rates. Patients with ACs that are IHC positive can be 
fast tracked towards receiving targeted therapy. 
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Recommendations for future research 
1. The EGFR mutational rate was lower than expected. Future studies 
should compare EGFR IHC with PCR. It is our intention to do this 
should EGFR PCR become available at the NHLS. 
2. To assess the ALK mutational rate with ALK FISH and compare the 
sensitivity of the ALK IHC used in this study with ALK FISH.  
3. Accurate sub-classification of NSCC is the first step towards 
identifying the subset of lung cancers that may require further 
mutational analysis. We recommend consistent adherence to the 
guidelines as determined by Travis et al. (2011 and 2015).   
 
 
 
1). EGFR mutations and ALK translocations are seen in 9% and 7% of patients 
with lung adenocarcinoma in this cohort of patients from Johannesburg 
2). This study of 111 patients shows no significant correlation between EGFR 
mutation and the following variables: age, sex, race, histological tumour subtype 
and smoking history 
3). The ALK mutation shows a significant correlation with Black patients 
4). The ALK mutation in lung adenocarcinoma appears higher in the South 
African population (7%) than in some other international population groups (2-
7%) 
5). Squamous carcinoma is more common (46%) than adenocarcinoma (39%) in 
this study of primary lung carcinoma and the global shift in trend towards 
adenocarcinoma is not demonstrated in this study group    
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Variable Names and Variable values 
Study no: 
 
Path no: 
 
Year of biopsy: 
Hospital: CMJAH = 1 HJH = 2 
Patient demographics  
Race:  Black = 1 White = 2 Coloured = 3 Indian = 4 Uncertain= 5 
Age: 
 
Sex: Male = 1 Female = 2  Uncertain= 3 
Smoking hx  Not available= 1 ex-smoker = 2 current smoker/recently stopped smoking = 3 non-smoker= 4  
Occupation 
history OH  
Not available=1 miner (nos.)=2 not a miner=3 asbestos exposure=4 platinum miner=5 Flour 
mill=6 gold miner=7 coal miner= 8 
Biopsy (BX) site:  
Transbronchial=1 endobronchial=2 transthoracic=3 pleural=4 lymph node=5  lobectomy=6 open lung 
biopsy/wedge=7 mediastinal mass = 8 
Biopsy (BX) 
diagnosis:  
(AC)Adenocarcinoma=1 (ADSCC)Adenosquamous carcinoma=2 (LC)large cell carcinoma=3 
(NSCLC)Non small cell lung cancer (nos.)=4  combined tumour=5 (SCC)Squamous carcinoma=6 
 
 (SCLC)Small cell carcinoma=7 Carcinoma (favour metastatic)=8 
ALK/EGFR SP125/EGFR111: negative=1 positive=2 no tumour on slide=3 no tissue/block for IHC=4 Not done=5 
TTF1/Napsin A/CK7/CK20/P63/CK5/6: negative=1 positive=2 no tumour on slide/block=3no tissue/block for                     
IHC=4 IHC Not done/No slide=5 
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Annexure 1: Data collection sheet 
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Year Original diagnosis  (n) Diagnosis after review (n) 
2014 AC 15 17 
 NSCC (nos.) 4 1 
 Metastatic AC 5 6 
 ADSCC 1 1 
 SCC 13 20 
2012 AC 30 32 
 LC 0 1 
 NSCC (nos.) 3 0 
 Metastatic  AC 7 7 
2011 AC 32 24 
 ADSCC 2 3 
 LC 0 1 
 SCC 30 34 
 Metastatic AC 7 8 
2010 AC 14 14  
 NSCC (nos.) 5 4 
 Metastatic AC 5 7 
2009 AC 7 6 
 NSCC (nos.) 1 0 
 Metastatic AC 8 10 
2008 AC 7 7 
 ADSCC 1 0 
 NSCC (nos.) 1 2 
 Metastatic  AC 1 2 
 
 
Annexure 2a: Reclassification of cancers based on recommended guidelines by 
Travis et al. (2011 and 2015) from 01 January 2008 to 30 June 2014 
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Annexure 2b: Reclassification of some cancers based on recommended guidelines 
by Travis et al. (2011 and 2015) from 01 January 2008 to 30 June 2014 
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Year  Total biopsies(n) Neoplastic biopsies (n) Non-neoplastic biopsies (n) 
2014  355 76 279 
2013 680 67 613 
2012 847 121 726 
2011 792 123 669 
2010 537 51 486 
2009 507 47 460 
2008 183 23 160 
TOTAL 3901 508 3393 
 
 
 
Year NSCC SCLC  Combined 
tumour * 
Other*** 
 AC SCC ADSCC NSCC(nos.)  LC    
2014 17 20 1 1 0 3 0 34 
2013 16 14 0 0 0 7 1** 29 
2012 32 22 0 0 1 10 0 56 
2011 24 34 3 2 1 7 0 52 
2010 14 15 0 4 0 3 0 15 
2009 6 13 1 0 0 4 0 22 
2008 7 10 0 1 0 2 0 3 
Total 117 128 5 8 2 36 1 211 
* Combined tumour = combination of a SCLC and NSCC 
**This tumour comprised a SCLC and a large cell neuroendocrine carcinoma (it did not 
contain an adenocarcinoma component) 
*** Other= mesothelioma, sarcoma, lymphoma, salivary glands tumours, metastatic 
carcinomas, thymoma, hamartoma and cytology specimens. 
 
 
 
Annexure 3a: Total biopsies received from CMJAH and HJH for the period 
1st January 2008 to 30th June 2014    
Annexure 3b: Biopsies received from CMJAH and HJH from 1st January 2008 to 
30th June 2014   
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Year Race Age Sex Smoking 
history 
Occupational 
history 
Positive IHC 
2009 B 67 M No NA EGFR SP111 
2011 B 61 F NA NA EGFR SP111 
2011 B 48 F No NA EGFR SP111 
2012 W 64 M No NA EGFR SP111 
2012 B 62 M Yes NA EGFR SP111 
2013 B 63 M Yes Yes** EGFR SP111 
2014 B 36 M No NA EGFR SP111 
2014 B 67 F No NA EGFR SP111 
2013 C 58 F Yes NA EGFR SP125 
2013 B 56 M Yes NA EGFR SP125 
** patient worked in a gold mine  
B = Black, W = White, C = Coloured, M = Male, F = Female  
NA= Not available 
 
 
Year Race Age Sex Smoking 
history 
Occupational 
history 
Positive IHC 
2009 B 44 M Yes Yes * ALK 
2010 B 71 M yes NA ALK 
2011 B 54 M No NA ALK 
2011 B 57 M Ex-
smoker 
NA ALK 
2012 B 28 F NA NA ALK 
2014 B 64 M Yes NA ALK 
2014 B 52 F No NA ALK 
2014 B 41 M NA NA ALK 
* patient worked in a flour mill 
B = Black, W = White, C = Coloured, M = Male, F = Female  
NA= Not available 
 
Annexure 4b: Demographic data, smoking history and occupational history on 
biopsies positive for the ALK mutation 
Annexure 4a: Demographic data, smoking history and occupational history on 
biopsies positive for the EGFR mutation 
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Histogram of age for EGFR 
 
 
 
Histogram of age for ALK  
  
Annexure 5: Histogram 
Age is consistent with a normal distribution, swilk test p= 0.3577 
Age is consistent with a normal distribution, swilk test p= 0.3008 
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Positive IHC Morphology Staining pattern Staining 
intensity 
EGFR SP111 Acinar Patchy homogenous 
cytoplasmic & membranous 
2+ 
EGFR SP111 Acinar Diffuse homogenous 
cytoplasmic & membranous 
3+ 
EGFR SP111 Lepidic, micropapillary Patchy homogenous 
cytoplasmic & membranous 
3+ 
EGFR SP111 Solid Patchy homogenous 
cytoplasmic & membranous 
3+ 
EGFR SP111 Acinar Diffuse homogenous 
cytoplasmic & membranous 
3+ 
EGFR SP111 Acinar Patchy homogenous 
cytoplasmic & membranous 
3+ 
EGFR SP111 Acinar, nests Patchy homogenous 
cytoplasmic & membranous 
3+ 
EGFR SP111 Acinar Patchy homogenous 
cytoplasmic & membranous 
2+ 
EGFR SP125 Acinar Patchy homogenous 
cytoplasmic & membranous 
2+ 
EGFR SP125 Acinar Patchy homogenous 
cytoplasmic & membranous 
2+ 
ALK D5F3 Acinar Diffuse granular cytoplasmic  3+ 
ALK D5F3 Solid Patchy granular cytoplasmic  3+ 
ALK D5F3 Acinar, cribriform Diffuse granular cytoplasmic 3+ 
ALK D5F3 Solid Patchy granular cytoplasmic 3+ 
ALK D5F3 Papillary Diffuse granular cytoplasmic 3+ 
ALK D5F3 Acinar Diffuse granular cytoplasmic 3+ 
ALK D5F3 Solid, lepidic, papillary Patchy granular cytoplasmic 3+ 
ALK D5F3 Micropapillary Patchy granular cytoplasmic 3+ 
 
 
 
Annexure 6: Morphological pattern and scoring of IHC on biopsies positive 
for the EGFR and ALK mutation 
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EGFR IHC: SP111 positive biopsies (A-H) 
A1 A2
Adenocarcinoma with acinar growth pattern at 10X magnification (A1) Haematoxylin 
and eosin, (A2) EGFR IHC with 2+ moderate, patchy cytoplasmic & focal membranous 
staining    
B1 B2  
Adenocarcinoma with acinar growth pattern at 10X magnification (B1) Haematoxylin 
and eosin, (B2) EGFR IHC with 3+ strong, diffuse cytoplasmic & membranous staining    
C1 C2  
Adenocarcinoma with micropapillary growth pattern at 10X magnification (C1) 
Haematoxylin and eosin, (C2) EGFR IHC with 3+ strong, patchy cytoplasmic & focal 
membranous staining    
Annexure 7: Photomicrographs showing morphological patterns and IHC staining on 
biopsies positive for the EGFR and ALK IHC 
100 
 
D1 D2  
Adenocarcinoma with solid growth pattern at 10X magnification (D1) Haematoxylin and 
eosin, (D2) EGFR IHC with 3+ strong, patchy cytoplasmic & focal membranous staining    
E1 E2  
Adenocarcinoma with acinar growth pattern at 10X magnification (E1) Haematoxylin 
and eosin, (E2) EGFR IHC with 3+ strong, diffuse cytoplasmic & focal membranous 
staining  
F1 F2  
Adenocarcinoma with acinar growth pattern at 10X magnification (F1) Haematoxylin and 
eosin, (F2) EGFR IHC with 3+ strong, patchy cytoplasmic & focal membranous staining    
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G1 G2  
Adenocarcinoma with acinar growth pattern at 10X magnification (G1) Haematoxylin 
and eosin, (G2) EGFR IHC with 3+ strong, patchy cytoplasmic & focal membranous 
staining    
H1 H2  
Adenocarcinoma with acinar growth pattern at 10X magnification (H1) Haematoxylin 
and eosin, (H2) EGFR IHC with 2+ moderate, patchy cytoplasmic staining) 
EGFR IHC: SP125 positive biopsies (I-J): 
I1 I2  
Adenocarcinoma with acinar growth pattern at 10X magnification (I1) Haematoxylin and 
eosin, (I2) EGFR IHC with 2+ moderate, patchy cytoplasmic &focal membranous 
staining    
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J1 J2  
Adenocarcinoma with acinar growth pattern at 10X magnification (J1) Haematoxylin and 
eosin, (J2) EGFR IHC with 2+ moderate, patchy cytoplasmic & focal membranous 
staining 
 
ALK IHC positive biopsies (K-R): 
K1 K2  
Adenocarcinoma with acinar growth pattern at 10X magnification (K1) Haematoxylin 
and eosin, (K2) ALK IHC with 3+ strong diffuse granular cytoplasmic staining 
L1 L2  
Adenocarcinoma with solid growth pattern at 10X magnification (L1) Haematoxylin and 
eosin, (L2) ALK IHC with 3+ strong patchy granular cytoplasmic staining 
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M1 M2  
Adenocarcinoma with cribriform growth pattern at 10X magnification (M1) Haematoxylin 
and eosin, (M2) ALK IHC with 3+ strong diffuse granular cytoplasmic staining 
N1 N2  
Adenocarcinoma with solid growth pattern at 10X magnification (N1) Haematoxylin and 
eosin, (N2) ALK IHC with 3+ strong patchy granular cytoplasmic staining 
O1 O2  
Adenocarcinoma with papillary growth pattern at 10X magnification (O1) Haematoxylin 
and eosin, (O2) ALK IHC with 3+ strong diffuse granular cytoplasmic staining 
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P1 P2  
Adenocarcinoma with acinar growth pattern at 10X magnification (P1) Haematoxylin 
and eosin, (P2) ALK IHC with 3+ strong diffuse granular cytoplasmic staining 
Q1 Q2  
Q3 Q4  
Adenocarcinoma at 10X magnification (Q1) Solid, (Q2) lepidic, (Q3) papillary growth 
patterns, Haematoxylin and eosin; (Q4) ALK IHC with 3+ strong patchy granular 
cytoplasmic staining 
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R1 R2  
Adenocarcinoma with micropapillary growth pattern at 10X magnification (R1) 
Haematoxylin and eosin, (R2) ALK IHC with 3+ strong patchy granular cytoplasmic 
staining 
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Annexure 8: Approval letter from Dr Sophia Kisting, NIOH executive director 
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Annexure 9: Ethics Clearance certificate: M140943 
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Annexure 10: Protocol approval  
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Annexure 11: Turnitin 
